Systematic Review

Do Regenerative Medicine Therapies Provide Long-Term Relief in Chronic Low Back Pain: A Systematic Review and Metaanalysis

Jaya Sanapati, MD[1], Laxmaiah Manchikanti, MD[2], Sairam Atluri, MD[3], Sheldon Jordan, MD[4] Sheri L. Albers, DO[5], Miguel A. Pappolla, MD, PhD[6], Alan D. Kaye, MD, PhD[7], Kenneth D. Candido, MD[8], Vidyasagar Pampati, MSc[2], and Joshua A. Hirsch, MD[9]

From: [1]University Pain Medicine and Rehabilitation Center, Newark, NJ; [2]Pain Management Center of Paducah, Paducah, KY; [3]Tri-State Spine Care Institute, Cincinnati, OH; [4]Neurological Associates of West Los Angeles, the Interventional Group, Santa Monica, CA and UCLA Department of Neurology, Los Angeles, CA; [5]Radiology Research and Consultation, Sacramento, CA; [6]St. Michael's Pain and Spine Clinics, Houston, TX, and Univeristy of Texas Medical Branch, Galveston, TX; [7]LSU Health Science Center, New Orleans, LA; [8]Advocate Illinois Masonic Medical Center and University of Illinois College of Medicine, Chicago, IL; [9]Massachusetts General Hospital and Harvard Medical School, Boston, MA

Additional Author Affiliation Information on P. 533

Address Correspondence: Laxmaiah Manchikanti, MD 2831 Lone Oak Road Paducah, Kentucky 42003 E-mail: drlm@thepainmd.com

Disclaimer: There was no external funding in preparation of this manuscript. Conflicts of Interest: Dr. Manchikanti has provided limited consulting services to Semnur Pharmaceuticals, Incorporated, which is developing nonparticulate steroids. Dr. Jordan is Chief Investigator for Emcyte. Dr. Kaye is a speaker for Depomed, Inc. and Merck. Dr. Hirsch is a consultant for Medtronic.

Manuscript received: 10-05-2018
Revised manuscript received: 110-27-2018
Accepted for publication: 11-02-2018

Free full manuscript: www.painphysicianjournal.com

Background: Several cell-based therapies have been proposed in recent years the management of low back pain, including the injection of medicinal signaling cells or mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP). However, there is only emerging clinical evidence to support their use at this time.

Purpose: To assess the effectiveness of MSCs or PRP injections in the treatment of low back and lower extremity pain.

Study Design: A systematic review and metaanalysis of the effectiveness of PRP and MSCs injections in managing low back and lower extremity pain.

Data Sources: PubMed, Cochrane Library, US National Guideline Clearinghouse, prior systematic reviews, and reference lists. The literature search was performed from 1966 through June 2018.

Study Selection: Randomized trials, observational studies, and case reports of injections of biologics into the disc, epidural space, facet joints, or sacroiliac joints.

Data Extraction: Data extraction and methodological quality assessment were performed utilizing Cochrane review methodologic quality assessment and Interventional Pain Management Techniques - Quality Appraisal of Reliability and Risk of Bias Assessment (IPM-QRB) and Interventional Pain Management Techniques – Quality Appraisal of Reliability and Risk of Bias Assessment for Nonrandomized Studies (IPM-QRBNR). The evidence was summarized utilizing principles of best evidence synthesis on a scale of 1 to 5.

Data Synthesis: Twenty-one injection studies met inclusion criteria. There were 12 lumbar disc injections, 5 epidural, 3 lumbar facet joint, and 3 sacroiliac joint studies

Results: Evidence synthesis based on a single-arm metaanalysis, randomized controlled trials (RCTs), and observational studies, disc injections of PRP and MSCs showed Level 3 evidence (on a scale of Level I through V). Evidence for epidural injections based on single-arm metaanalysis, a single randomized controlled trial and other available studies demonstrated Level 4 (on a scale of Level I through V) evidence. Similarly, evidence for lumbar facet joint injections and sacroiliac joint injections without metaanalysis demonstrated Level 4 evidence (on a scale of Level I through V)..

Limitations: Lack of high quality RCTs.

Conclusion: The findings of this systematic review and single-arm metaanalysis shows that MSCs and PRP may be effective in managing discogenic low back pain, radicular pain, facet joint pain, and sacroiliac joint pain, with variable levels of evidence in favor of these techniques.

Key Words: Chronic low back pain, regenerative therapy, medicinal signaling or mesenchymal stem cells, platelet-rich plasma, disc injection, lumbar facet joint injections, sacroiliac joint injections

Pain Physician 2018: 21:515-540

The growing number of modalities for management of chronic low back pain, along with the prevalence of this condition, has contributed to its high socioeconomic burden (1-4). Growing costs, in conjunction with the alleged low quality of some studies has had a negative impact on care health policy (1-13). In an assessment of U.S. spending on personal health care and public health, Dieleman et al (3) demonstrated that out of 155 defined conditions, low back and neck pain showed the second highest increase in spending, estimated to be around $57.2 billion (uncertainty interval $47.4 billion - $64.4 billion), from 1996 to 2013. In addition, low back and neck pain were the conditions that received the third highest level of health care spending, estimated at $87.6 billion in the context of a total of $183.5 billion spent for musculoskeletal disorders (3,4).

Diagnostic studies have demonstrated that the most common sources of low back pain include the intervertebral discs, the zygapophysial (facet), and the sacroiliac joints (13-19). Discogenic pathology, with or without internal disc derangement, has been estimated to contribute from 16.9% to 39% of cases of chronic low back pain without radiculopathy. In addition, lumbar disc disorders may manifest as disc prolapse, protrusion, extrusion, and herniation (13). According to the literature, the prevalence of symptomatic lumbar disc herniation is approximately 1% to 3%, whereas the prevalence of lumbar radiculopathy and sciatica is 0.98% (13-21). Similarly, the lumbosacral facet joints are well-recognized generators of chronic low back and referred lower extremity pain. Controlled studies have shown that the facets are responsible for generating low back pain that is not radicular or discogenic in 16% to 41% of cases (14). In addition, studies based on controlled diagnostic blocks have implicated the sacroiliac joints in 10% to 25% of low back pain cases without disc herniation, discogenic pain, or radiculitis (15).

Pain related to disc degeneration, disc herniation, and facet or sacroiliac joint pathology may be self-limited, but in a significant proportion of patients, this pain may become chronic, requiring the extensive treatment applications. Many of the decisions made in the management of these disorders are not supported by randomized controlled trials (RCTs) or well-designed observational studies (22).

Treatment modalities in the management of chronic lumbosacral pain include, conservative management with physical therapy, pharmacological therapy, interventional and intradiscal as well as surgical intervention through fusion or disc replacement. Multiple regulations have put in place to improve the standard of care and reduce healthcare costs (10,14-17,23-54). It is known that in disc degeneration, inflammatory cytokines produced by macrophages or disc cells play important roles in pain generation (55-66). As a result, in addition to traditional treatments, several cell-based therapies have recently been proposed including injections of medicinal signaling cells or mesenchymal stem cells (MSCs) or platelet-rich plasma (PRP). Evidence regarding these therapies has emerged from the basic sciences and has been translated into clinical research through controlled trials.

The available literature includes 4 systematic reviews and multiple additional manuscripts that assess the role of regenerative medicine therapies in treating lumbosacral degenerative disorders (58-66). Wang et al (58) studied the efficacy of intervertebral disc regeneration using stem cells in a systematic review and metaanalysis of controlled animal trials. Khan et al (59) performed a systematic review on the use of mesenchymal stem cells (MSCs) in spinal cord injury, intervertebral disc repair, and spinal fusion and concluded that MSCs possess an immune-modulatory role and can be used safely and effectively for spinal cord injury and disc repair (59). In a consensus statement on biologic treatments for orthopedic injury, LaPrade et al (63) discussed the evidence supporting the potential use of biologics for promotion of healing and function in patients with musculoskeletal injury. Basso et al (60) performed a systematic review of the clinical evidence of regenerative medicine in intervertebral disc degeneration with a focus on the role of PRP and MSCs. This review encompassed 7 articles on regenerative therapies that studied a combined population of only 104 patients. It also summarized the literature highlighting the potential of intradiscal injection of MSC or PRP in treating chronic low back pain due to underlying degenerative disc disease. Wu et al (61) conducted a systematic review and a single-arm metaanalysis of 6 reports on cell-based therapies for lumbar discogenic pain, and concluded that these therapies were associated with improvements in pain and disability scores.

However, the roles of biologicals in epidural injections, lumbar facet joint injections, and sacroiliac joint injections remains to be defined. The following systematic review and metaanalysis was therefore undertaken to evaluate the effectiveness of regenerative medicine therapies and their potential applications in the management of chronic low back pain.

1.0 Methods

The present systematic review was performed based on methodological and reporting quality of systematic reviews as described by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and A Measurement Tool to Assess Systematic Reviews (AMSTAR) (67-70). The step-wise compliance of PRISMA checklist was utilized (67,68).

This review focuses on the effectiveness of regenerative therapy in managing lumbosacral disorders which have resulted in chronic pain.

1.1 Eligibility Criteria

1.1.1 Types of Trials

- Randomized controlled trials
- Observational studies
- Case reports

1.1.2 Types of Participants

Patients in chosen trials had been suffering with chronic low back and/or lower extremity pain secondary to disc herniation, discogenic pathology without disc herniation, radiculitis or facet joint arthropathy, spinal stenosis, post-surgery syndrome, lumbar facet joint pain and sacroiliac joint pain.

1.1.3 Types of Interventions

Intradiscal, intraarticular, epidural and sacroiliac joint injections.

1.1.4 Types of Outcome Measures

- The primary outcome parameter was pain relief.
- The secondary outcome measure was functional status improvement.

1.2 Data Sources

All available trials in all languages, from all countries, providing appropriate management with outcome evaluations were considered for inclusion. Searches were performed from the following sources without language restrictions:

1. PubMed from 1966
   www.ncbi.nlm.nih.gov/pubmed
2. Cochrane Library
   www.thecochranelibrary.com
3. US National Guideline Clearinghouse (NGC)
   www.guideline.gov/
4. Previous systematic reviews and cross references
5. Clinical Trials
   www.clinicaltrials.gov/
6. All other sources including non-indexed journals and abstracts

The search period was from 1966 through June 2018.

1.3 Search Strategy

Search criteria were extensive, covering chronic low back pain of various origins along with multiple methods of injection of biologicals including PRP and stem cells.

Search strategy was as follows: ((((((((((((((((chronic low back pain) OR chronic mid back OR upper back pain) OR disc herniation) OR discogenic pain) OR herniated lumbar discs) OR nerve root compression) OR lumbosciatic pain) OR postlaminectomy) OR lumbar surgery syndrome) OR radicular pain) OR radiculitis) OR sciatica) OR spinal fibrosis) OR spinal stenosis) AND ((((((((((epidural injection) OR platelet rich plasma injection or stem cell injection) OR epidural perineural injection) OR interlaminar epidural) OR intraarticular platelet rich plasma) OR stem cells) OR nerve root blocks) OR periradicular infiltration) OR transforaminal injection) OR platelet rich plasma OR stem cells) OR intradiscal injections or PRP or stem cells or sacroiliac joint or ligament injections or PRP or stem cells))) AND ((meta-analysis [pt] OR randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp])))

1.4 Data Collection and Analysis

This review focused on all types of evaluations of PRP and stem cell injections. All studies that provided appropriate management and included outcome evaluations and statistical evaluations were reviewed. Book chapters, case reports, and reports without an appropriate diagnosis were excluded from consideration.

1.4.1 Inclusion Criteria

This review focused only on studies of effectiveness. The population of interest was patients suffering from chronic low back pain. Patients with acute trau-

ma, fractures, malignancies, and inflammatory diseases were excluded.

All randomized trials with appropriate statistical calculations were utilized. Observational studies with a sample size of at least ten subjects were included.

1.4.2 Data Collection Process

Two review authors independently, in an unblinded, standardized manner, developed a search strategy, searched for relevant literature, selected manuscripts, and extracted data from the included studies. Disagreements were resolved by discussion between the 2 reviewers; if no consensus could be reached, a third author was called in to break the tie. If there was a conflict of interest regarding a reviewed manuscript (concerning authorship), or if the reviewer was also one of the authors or had any other type of conflict, the involved reviewer did not review the manuscript for methodologic quality assessment.

1.5 Data Synthesis and Analysis

Data synthesis and analysis were performed, including assessment of the risk of bias or quality of individual studies, outcomes assessment, and qualitative and quantitative analysis.

1.5.1 Risk of Bias of Individual Studies

The quality of each individual article used in this analysis was assessed using the Cochrane Review rating system (Appendix Table 1) (71) and Interventional Pain Management Techniques -- Quality Appraisal of Reliability and Risk of Bias Assessment Tool (IPM – QRB) for randomized controlled trials (Appendix Table 2) (72), and Interventional Pain Management Techniques – Quality Appraisal of Reliability and Risk of Bias Assessment for nonrandomized or observational studies (IPM-QRBNR) (Appendix Table 3) (73).

Utilizing the Cochrane Review criteria, studies meeting at least 9 of the 13 inclusion criteria were considered high-quality. Those meeting 5 to 8 criteria were considered moderate-quality, and those meeting fewer than 5 criteria were considered low quality and were excluded.

Based on the IPM-QRB and IPM-QRBNR criteria, studies meeting the inclusion criteria but scoring less than 16 were considered low quality and were excluded, studies scoring from 16 to 31 were considered moderate quality; and studies scoring from 32 to 48 were considered high quality and were included.

Methodologic quality assessment of each manuscript was performed by 2 review authors. The assessment was carried out independently in an unblinded, standardized manner to assess the methodologic quality and internal validity of all the studies considered for inclusion. If discrepancies occurred, a third reviewer performed an assessment, and a consensus was reached. Further remaining issues were discussed by all reviewers and were then resolved.

1.5.2 Outcome of the Studies

For the present analysis, either 50% relief from the baseline pain score or a change of at least 3 points on an 11-point pain scale of 0 to 10 was considered clinically significant. For functional status improvement, a change of 30% or more on disability scores or 50% improvement from baseline was considered clinically significant.

A study was judged to be positive if the relevance and effectiveness of the regenerative injection therapy of interest was demonstrated with either a control group or upon comparison from baseline to follow-up. A negative study was defined as one where no difference was seen between the treatments or where no improvement from baseline could be measured. Reference point measurements were considered at 3 months, 6 months, and one year.

1.6 Analysis of Evidence

The analysis of the evidence was performed based on best-evidence synthesis and was modified and collated using multiple available criteria, including the Cochrane Review criteria and United States Preventive Task Force (USPSTF) criteria as illustrated in Table 1 (74). The analysis was conducted using 5 levels of evidence ranging from strong to opinion- or consensus-based. The results of best evidence as per grading were utilized. At least 2 of the review authors independently, in an unblinded, standardized manner, analyzed the evidence. Any disagreements between reviewers were resolved by a third author and consensus was attained. If there were any conflicts of interest (e.g., authorship), the reviewers of interest were recused from assessment and analysis.

1.6.1 Metaanalysis

The metaanalysis was performed using Comprehensive Metaanalysis version 3.0 (Biostat Inc., Englewood, NJ). For pain and functional status improvement data, the studies were reported as standardized mean differences (SMD) with 95% confidence intervals (CI). Data were plotted with forest plots to evaluate treat-

Table 1. *Qualitative modified approach to grading of evidence.*

Level I	Strong	Evidence obtained from multiple relevant high quality randomized controlled trials for effectiveness
Level II	Moderate	Evidence obtained from at least one relevant high quality randomized controlled trial or multiple relevant moderate or low quality randomized controlled trials
Level III	Fair	Evidence obtained from at least one relevant high quality nonrandomized trial or observational study with multiple moderate or low quality observational studies
Level IV	Limited	Evidence obtained from multiple moderate or low quality relevant observational studies
Level V	Consensus Based	Opinion or consensus of large group of clinicians and/or scientists for effectiveness as well as to assess preventive measures, adverse consequences, effectiveness of other measures.

Adapted from Manchikanti L, Falco FJE, Benyamin RM, Kaye AD, Boswell MV, Hirsch JA. A modified approach to grading of evidence. Pain Physician 2014; 17:E319-E325 (74).

ment effects. Heterogeneity was interpreted through I^2 statistic.

Random-effects model (single-arm) metaanalysis was planned to assess net changes in the same outcome variable (61,75). Heterogeneity among the effect sizes of individual studies was assessed using the I^2 index and Q statistic. Heterogeneity analyzed with the I^2 statistic was defined as low (25%–50%), moderate (50%–75%), or high (>75%) (76). Subgroup analyses were conducted based on follow-up periods (6 vs. 12 months or more) and the injected biologic solution type (stem cell vs. PRP). We conducted meta-regression analysis to identify factors related to a decrease in the pain score following therapy.

All analyses were based on each modality of treatment and the solution injected. Short-term improvement was defined as any improvement lasting for at least 3 months, and long-term improvement was described as that lasting for 6 months or longer. Meta-analysis was performed only when at least 3 studies were available and included an appropriate sample size of at least 10 for nonrandomized studies.

2.0 Results

2.1 Study Selection

Figure 1 shows a flow diagram of the study selection using the PRISMA study selection process (67,68).

Based on the search criteria, 26 manuscripts were identified and considered for inclusion (62,77-101). A total of 23 studies met the inclusion criteria (62,77-81,83-86,89-101) following the removal of duplicate publications (78,79). Three studies on stem cell therapy were excluded due to the inclusion of fewer than 10 participants (82,87,88). Of the remaining twenty studies, one utilized 3 modalities of treatment (92).

2.2 Methodologic Quality and Risk of Bias Assessment

Of the 21 manuscripts meeting inclusion criteria (62,77,80,81,83-86,89-101), 5 were randomized trials (85,90,94,95,101). Appendix Tables 4 and 5 show the methodologic quality assessment and risk of bias in each of these trials utilizing the Cochrane review criteria and the IPM-QRB criteria respectively (85,90,94,95,101). Assessment by the Cochrane review criteria showed that all of the trials were high-quality. However, assessment by IPM-QRB showed only 4 trials to be of high quality (85,90,94,101), with the remaining one trial of moderate quality (95).

Appendix Table 6 shows the assessment of the included nonrandomized or observational studies, including case reports, utilizing IPM-QRBNR criteria. Sixteen studies were included in this category for various types of regenerative medicine injection procedures in the lumbosacral spine (62,77,80,81,83,84,86,89,91-93,96-100). However, none of these were shown to be of high quality. The majority were moderate-quality (62,77,80,81,83,84,86,89,91-93,96,98-100) with one low-quality study (97).

2.3 Lumbar Disc Injections

Evidence of the effectiveness of PRP injections and injections of MSCs has been assessed through systematic reviews, randomized trials, and multiple observational studies.

2.3.1 Platelet-Rich Plasma

Our search identified multiple manuscripts on the utilization of PRP for intradiscal injections. These included a systematic review (60) and 6 individual studies, of which one was an RCT (90), and 5 were observational studies (80,81,89,91,92). The systematic review



Fig. 1. *Flow diagram illustrating published literature evaluating regenerative therapies in lumbosacral disorders.*

(60) included the RCT (90) and 2 of the observational studies (81,91). Methodologic quality assessment and risk of bias assessment showed the RCT (90) to be of high quality based on the Cochrane review criteria and IPM-QRB criteria as shown in Appendix Tables 4 and 5. All the observational studies were shown to be of moderate quality (80,81,89,91,92) as assessed by IPM-QRBNR criteria and shown in Appendix Table 6.

Study characteristics are described in Table 2. Appendix Table 7 shows the study details of the numerical rating scale (NRS) and the visual analog scale (VAS) data at various follow-up time points.

As this search revealed only one RCT of interest (90), a 2-arm metaanalysis was not feasible. Thus, a single-arm metaanalysis was performed with inclusion of all studies. However, as demonstrated in Appendix

Table 2. *Characteristics and outcomes of studies of PRP in intervertebral disc degeneration.*

Study Details	Chronicity of Injury and Biologic Used	Follow-up Period	Conclusions
Tuakli-Wosornu et al, 2016 (90) Lumbar discogenic pain Prospective, double-blind, randomized controlled study, n=47	Chronic PRP injections	One year	Intradiscal injections of PRP x1 showed significant improvement at 8-week follow-up, with maintained improvement compared to controls at 1-year follow-up.
Monfett et al, 2016 (89) Lumbar discogenic pain, lumbar disc degeneration Prospective trial, n=29	Chronic PRP injections	2 years	Intradiscal PRP injections show continued safety and improvements in pain and function at 2 years post-procedure
Navani et al, 2018 (80) Lumbar discogenic pain Prospective case series n=14	Chronic PRP, single injection, 2mL injected up to 3 disc levels	18 months	At 18 months, 11 patients remained for survey compared to 13 patients surveyed at 6 months. VAS relief was (>=50%) in 100% of patients at 18 months (n=11/11) and in 85% of patients (n=11/13) at 6 months.
Akeda et al, 2017 (91) Lumbar discogenic pain Preliminary clinical trial, n=14	Chronic PRP injections	12 months	Intradiscal injection of autologous PRP releasate in patients with low back pain was safe with no adverse events observed during follow-up The results showed reduction in mean pain scores at one month, sustained throughout the observation periods of 6 months and 12 months.
Levi et al, 2016 (81) Lumbar discogenic pain Prospective trial, n=8	Chronic PRP, single injection	6 months	Single or multiple levels (up to 5) of discogenic pain injected with PRP showed encouraging improvement, with more patients developing improvement over time. Cohort up to 6 months.
Kirchner and Anitua, 2016 (92) Lumbar disc degeneration Observational retrospective pilot study, n=86	Chronic PRGF-Endoret	6 months	Fluoroscopy-guided infiltrations of intervertebral discs and facet joints with PRGF in patients with chronic LBP resulted in significant pain reduction assessed by VAS. The results showed reduction of the VAS over time. The study ended at 6 months with 91% of the patients showing an excellent score, 8.1% showing moderate improvement, and 1.2% showing lack of response.

PRP = platelet-rich plasma; PRGF = plasma rich in growth factors; VAS = Visual Analog Scale; SF-36= 36-item Short Form Survey

Table 7, study details of the RCT were only available for 8 weeks. Consequently, the data from the RCTs was not included in long-term assessment. Figure 2 shows single-arm metaanalysis of decreased pain score data after 6-month follow-up. Five of the studies assessed showed a decrease in pain scores following treatment with a pooled sample size of 165 (80,81,89,91,92). The pooled mean difference in pain scores from baseline to 6-month follow-up was 40.631 ± 14.00 points (95% CI: -68.07 to -13.19, $P < 0.0001$, I^2 97.8%). Heterogeneity across studies was high ($I^2 = 98\%$).

Figure 3 shows pain relief data on the 12-month follow-up. Three studies were included showing a decrease in pain scores after treatment with a pooled sample size of 57 (80,89,91). The pooled mean difference in pain scores from baseline to the 12-month follow-up was 36.408 ± 8.114 points (95% CI: -62.311 to -20.51 $P < 0.003$, I^2 82.9%). Heterogeneity across studies was high ($I^2 = 83\%$). The authors of the 3 studies utilized different tools for functional improvement, and detailed data was not available. As a result, a metaanalysis of functional improvement data was not feasible.



Fig. 2. *Decreased pain score (numerical rating scale or visual analog scale, 0-100) after treatment (6-month follow-up data) of lumbar disc injections of PRP.*



Fig. 3. *Pain scores (numerical rating scale or visual analog scale, 0-100) after treatment (12-month follow-up data) with lumbar disc PRP injections.*

2.3.2 Mesenchymal Stem Cells or Medicinal Signalling Cells

Mesenchymal stem or medicinal signally cell (MSCs) therapy has been studied with multiple preclinical, clinical studies along with systematic reviews (60-62,77-79,82-88). In a systematic review, Basso et al (60) reviewed 3 manuscripts (79,82,84) exploring MSCs use in intervertebral disc disease. The second systematic review, a single arm metaanalysis by Wu et al (61), included 6 studies which were eligible for the review (62,78,82-84,87). Our search criteria identified a total of 9 manuscripts studying cell-based therapies for lumbar discogenic low back pain (62,77-79,82-88). Of these, there was one RCT (85), 3 manuscripts reporting a single study (77-79), 2 studies that each included 2 patients (87,88), and one study that included 9 patients (82). Consequently, 6 studies met inclusion criteria (62,77,83-86). The methodologic quality and risk of bias assessment of these studies showed high quality evidence for one RCT (85) based on both Cochrane review criteria and IPM-QRB criteria as shown in Appendix Tables 4 and 5. Five observational studies meeting inclusion criteria showed moderate quality (62,77,83,84,86) utilizing IPM-QRBNR criteria as shown in Appendix Table 6.

Appendix Table 8 shows the study features of cell therapy in discogenic pain presenting the average numerical rating scale (NRS) or visual analog scale (VRS) at different time points. Appendix Table 9 shows the average Oswestry Disability Index (ODI) at various time points for all the studies. Table 3 shows the characteristics and outcomes of the stem cell therapy in lumbar discogenic pain studies.

With only a single RCT (85), a 2-arm metaanalysis was not feasible. A single-arm metaanalysis was thus performed utilizing the 6 available studies including one RCT (62,77,83,84,85,86).

Table 3. *The characteristics and outcomes of the included studies of stem cell therapy in disc degeneration.*

Study Details	Population	Cell/Solution Type	Cell or Solution Dose and Delivery Pathway	Outcome Parameters	Results	Conclusion
Noriega et al, 2017 (85) Sample size = 24 Follow-up = 12 months RCT	24 patients with chronic low back pain with lumbar disc degeneration and unresponsive to conservative treatments were randomized into 2 groups. Patient age (yrs) mean age ± SE = 38±2 s	Allogeneic bone marrow MSCs by intradiscal injection or a sham infiltration of paravertebral musculature with anesthetic	The intervention group received allogeneic bone marrow MSCs by intradiscal injection of 25 X 10, 6 cells per segment under local anesthesia	VAS, ODI, MRI, SF-12	• MSC-treated patients displayed a quick and significant improvement in all algofunctional indices versus the controls. • Both lumbar pain and disability were significantly reduced at 3 months and improvement was maintained at 6 and 12 months. Overall there was an average 28% improvement in pain and disability one-year after the intervention. • Only 5 of the 12 outcomes in patients (40%) receiving MSCs were described as perfect treatment with 100% improvement.	• 28% improvement in all patients • 40% of patients perfect result • Positive result
Pettine et al, 2015, 2016, 2017 (77-79) Sample size =26 Follow-up=3 years Prospective, open-label, non-randomized, 2-arm study	26 patients presented with symptomatic moderate to severe discogenic low back pain Patient age (yrs)= 18–61 years (median 40)	Autologous bone marrow concentration (nonexpanded)	2–3mL of bone marrow concentrate was injected in lumbar disc (1.66_106/mL)	ODI, VAS, and MRI	• The average ODI and VAS scores were reduced to 22.8 and 24.4 at 3 months. After 36 months, 6 patients proceeded to surgery. • After 36 months, 20 of the 26 patients reported average ODI and VAS improvement to 17.5 ± 32 and 21.9 ± 4.4 respectively. • One year MRI indicated 40% of patients improved one modified Pfirrmann Grade and no patient worsened radiographically.	• At 36-month follow-up, 6 of 26 patients progressed to surgery. The remaining 20 patients (77%) reported significant ODI and VAS improvements. • Authors concluded that there were no adverse effects and the study provided evidence of safety and feasibility of intradiscal BMC therapy.
Coric et al, 2013 (83) Sample size =15 Follow-up=1 year Prospective cohort	15 patients with single-level, symptomatic lumbar DDD from L-3 to S-1 and medically refractory low back pain Patient age (yrs)= 19–47 years (median 40)	Expanded allogeneic juvenile chondrocyte cells	Mean 1.3mL (1–2 mL, 107/mL) cells solution was injected in the center of the disc space	ODI and NRS scores, 36-item Short Form Health Survey and MRI	• The mean ODI, NRS, and SF-36 physical component summary scores all improved significantly from baseline • Ten (77%) of these 13 patients exhibited improvements on MRI. Of these, the HIZ was either absent or improved in 8 patients (89%) by 6 months • Of the 10 patients who exhibited radiological improvement at 6 months, findings continued to improve or were sustained in 8 patients at the 12-month follow-up • Only 3 patients (20%) underwent total disc replacement by the 12-month follow-up due to persistent, but not worse than baseline, LBP	• The results of this prospective cohort are promising with 77% of patients improving • Positive result

Table 3 (cont.). *The characteristics and outcomes of the included studies of stem cell therapy in disc degeneration.*

Study Details	Population	Cell/Solution Type	Cell or Solution Dose and Delivery Pathway	Outcome Parameters	Results	Conclusion
Orozco et al, 2011 (84) Sample size =10 Follow-up=1 year Pilot phase 1 trial	10 patients with degenerative disc disease and persistent low-back pain (>6 months; decrease of disc height >50%;) Patient age (yrs)= 35_7 (mean_SD)	Autologous expanded bone marrow–derived mesenchymal stem cells	23±5X106 autologous expanded BMSCs was injected into the nucleus pulposus area	ODI and VAS scores and MRI	• Patients exhibited rapid improvement of pain and disability (85% of maximum in 3 months) that approached 71% of optimal efficacy • This study confirmed feasibility and safety with identification of strong indications of clinical efficacy	• Authors concluded that MSC therapy may be a valid alternative treatment for chronic back pain caused by degenerative disc disease. • They also concluded that advantages over current gold standards include simpler and more conservative intervention without surgery, preservation of normal biomechanics, and same or better pain relief
Kumar et al, 2017 (86) Sample size = 10 Follow-up = 1 year Phase 1 study	10 patients with chronic low back pain lasting for more than 3 months with a minimum intensity of 4/10 on a visual analog scale and disability level ≥ 30% on the Oswestry Disability Index. Patient age (yrs)=between 19 & 70	Combined hyaluronic acid derivative and adipose-tissue derived mesenchymal stem cells (AT-MSCs)	A single intradiscal injection at a dose of 2 X 107 cells/disc (N=5) or 4 X 107 cells/ disc (N=5)	VAS, ODI, Short-form 36, lumbar spine x-ray, MRI	• VAS, ODI, and SF-36 scores significantly improved in both groups receiving both low and high cell doses, and did not differ significantly between the 2 groups ● At 12-month follow-up 7 patients reported 50% or greater improvement in VAS ● 6 patients achieved treatment success with pain reduction of 50% or greater and improvement on disability scores on ODI • Among 6 patients who achieved significant improvement in VAS, ODI, and SF-36, 3 patients were determined to have increased water content based on an increased apparent diffusion coefficient on diffusion MRI	60% significant improvement with no adverse effect • Authors concluded that combined implantation of AT-MSCs and hyaluronic acid derivative in chronic discogenic low back pain is safe and tolerable • Positive result
Mochida et al (82) Sample size =9 Follow-up=3 years Prospective clinical study	9 patients with Pfirrmann grade III disc degeneration and posterior lumbar intervertebral fusion. Patient age (yrs)=20-29 years	Autologous cultured nucleus pulposus chondrocytes that cocultured with MSCs	One million activated autologous NP cells were injected into the degenerated disc 7 d after fusion surgery	JOA and MRI	• Clinical outcomes based on Japanese Orthopedic Association (JOA) scoring system for low back pain showed significant improvement from 14.2 ± 4.8 points preoperatively to 27.2 ± 1.6 points at 3 years after transplantation of the activated NP cells (maximum possible score of 29 points) • The JOA scoring system also showed improvement in low back pain subscale from 1.2 ± 0.5 points preoperatively to 2.7 ± 0.2 points at 3 years after the transplantation with maximum possible score of 3 points for no pain • No adverse effects were observed during the -year follow-up period	• Significant improvement in function and pain scores was reported • This study confirmed the safety of activated NP cell transplantation, and the findings suggest the minimal efficacy of this treatment to slow the further degeneration of human intervertebral discs

Table 3 (cont.). *The characteristics and outcomes of the included studies of stem cell therapy in disc degeneration.*

Study Details	Population	Cell/Solution Type	Cell or Solution Dose and Delivery Pathway	Outcome Parameters	Results	Conclusion
Meisel et al, 2006 (62) Sample size =12 Follow-up=2 years	Patients with discogenic pain after repeat discograms. Patients were treated with cell therapy at least 3 months post the endoscopic. Patient age (yrs)= 18–75 years	Autologous cultured disc-derived chondrocytes (from surgical treatment of their disc prolapse)	Cells are injected into disc approximately 12 weeks following discectomy. The cell dose was not mentioned	ODI and VAS scores and MRI	• The median total Oswestry Score was 2 in the autologous disc chondrocyte transplantation (ADCT) group compared with 6 in the control group. Decreases in the Disability index in autologous disc chondrocyte transplantation (ADCT)-treated patients correlated with the reduction of low back pain • Decreases in disc height over time were only found in the control group, and of potential significance, intervertebral discs in adjacent segments appeared to retain hydration when compared to those adjacent to levels that had undergone discectomy without cell intervention	• Significant improvement • Positive result

RCT = randomized controlled trial; BMSCs= Bone marrow derived stem cells; MSCs=mesenchymal stem cells; JOA = Japanese Orthopedic Association; MRI = magnetic resonance imaging; NP = nucleus pulposus; DDD=degenerative disc disease; BMC = bone marrow concentrate; LBP=low back pain; NRS = Numerical Rating Scale; ODI = Oswestry Disability Index; VAS =Visual Analog Scale; SD=standard deviation; SF-12=12-item short-form survey; HIZ-high intensity zone

Based on a single arm analysis, Fig. 4 shows changes in the pain scores. Inclusion of the 6 studies revealed a pooled sample size of 71 (62,79,83-86). The pooled mean difference of the decrease in pain scores from baseline to the 12 month follow-up was 36.943 points (95% CI: -49.855 to -24.030, $P < 0.001$. Heterogeneity across studies was high (I^2 =86%).

Figure 5 shows the functional scores. Six studies showed an Oswestry Disability Index (ODI) assessment (62,79,83-85,100,). The data was available for 12 months. The pooled mean difference in disability scores from baseline to the 12-month follow-up was a 26.342 point decrease (95% CI: -32.359 to -20.325, $P < 0.001$). Heterogeneity across studies was moderate (I^2 =55%).

2.4 Epidural Injections

Multiple biologics have been administered epidurally in the management ofradicular pain (92,98-101). However, studies have been preliminary and there has been only one randomized, double blind, reference-controlled study (101). The other studies have been observational, either prospective or retrospective (92,98-100). There have not been any systematic reviews assessing epidural injections with biologics. Methodologic quality and risk of bias assessment of included studies of epidural injections showed one RCT of high quality (101) based on Cochrane review criteria and IPM-QRB criteria as shown in Appendix Tables 4 and 5. The assessment of observational studies by IPM-QRBNR demonstrated moderate quality for all the studies as shown in Appendix Table 6 (92,98-100). Appendix Tables 10 and 11 list pain relief and disability data.

Since there was only one randomized, double blind, controlled trial (101), a 2-arm systematic review was not feasible. Consequently, a single-arm systematic review and metaanalysis was performed (Fig. 6).

Table 4 shows summary characteristics of lumbar epidural injections of PRP studies.

2.5 Lumbar Facet Intraarticular Injections

Of the 3 available studies, only one was randomized comparing PRP to a local anesthetic combined with a corticosteroid (94). Methodologic quality assessment of lumbar facet intraarticular injections showed that one RCT (94) was of high quality by Cochrane review quality and IPM-QRB criteria as shown in Appendix Tables 4 and 5. The other 2 studies (92,93) demonstrated moderate quality based on IPM-QRBNR criteria as shown in Appendix Table 6. Of the 3 studies, 2 were performed



Fig. 4. *Changes in pain score (numerical rating scale or visual analog scale, 0-100) after treatment (12 months follow data) of cell therapy of lumbar disc.*



Fig. 5. *Changes in Oswestry Disability Index (ODI) after treatment (12 months follow data) of cell therapy of lumbar disc.*



Fig. 6. *Changes in pain scores (0-100) after treatment (6 months follow data) of epidural PRP injections.*

by one group of authors with a sample size of 19 (93) and 46 (94). The third study by Kirchner and Anitua (92) was a complicated study with multiple injections (intradiscal, facet joint, as well as transforaminal) and reported excellent results. Because of the limitations, we were unable to perform a metaanalysis on these studies. The summary characteristics of these studies are listed in Table 5.

2.6 Sacroiliac Joint Injection

The effectiveness of biologicals, specifically PRP, was studied in one RCT (95) and 2 observational studies

Table 4. *Summary of lumbar epidural injection PRP studies published to date*

Study Details	Population	Cell/Solution Type	Cell or Solution Dose and Delivery Pathway	Outcome Parameters	Results	Conclusion
Becker et al, 2007 (101) Sample size=84 Follow-up = 6 months Randomized controlled trial	84 patients with chronic lumbar radicular pain Patient age (yrs)=29-81 (mean 53.9)	IL-1 RA-enriched autologous conditioned serum (Orthokine; Autologous conditioned serum (ACS)	Transforaminal or perineural injection of ACS once per week for 3 consecutive weeks. Perineural space was approached through interlaminar space with injection of 1 mL of local anesthetic and autologous serum in Group 3. Group 1 and 2 received 1 mL of local anesthetic plus 10 mg of triamcinolone or 5 mg of triamcinolone	VAS, ODI	• Patients in all 3 groups improved comparably. Results were significant within each treatment group from week 12 to the final evaluation at week 26, injections with ACA showed a consistent pattern of superiority over both triamcinolone groups with VAS, with no significant difference for ODI among the groups	• ACS showed similar response to triamcinolone injection with local anesthetic initially; however, with significant improvement at 26 weeks with pain relief, but not with function. Results similar to local anesthetic and steroid injections • One of the limitations in this trial is that of multiple injections
Centeno et al, 2017 (99) Sample size=470 Follow-up=2 years Prospective registry	Patients suffering with lumbar radicular pain and MRI findings that were consistent with symptoms.	Platelet lysate	• Transforaminal or interlaminar epidural injection under fluoroscopic guidance. The final injectate consisted of plasma lysate 50% by volume, 4% lidocaine at 25% by volume, and compounded preservative free 100 to 200 nanograms per mL of hydrocortisone at 25% by volume • For transforaminal and interlaminar epidural injections, 3 to 5 cm3 volume was injected	Numeric Pain Score (NPS), Modified Single Assessment Numeric Evaluation (SANE) rating, Functional Rating Index (FRI)	• Patients treated with platelet lysate epidurals reported significantly lower NPS and FRI change scores at all time points compared to baseline • Posttreatment FRI change score means exceeded the minimal clinically important difference beyond one month • Average modified SANE rating showed 49.7% improvement at 24 months posttreatment • 29 or 6.3% patients reported mild adverse events related to treatment.	• Positive results with registry presenting real world data. • A large proportion of patients withdrawn • 36% of the patients failed to provide baseline NPS data • Information on number of procedures is unknown • 26% of the patients failed to show any significant improvement
Kumar et al, 2015 (100) Sample size=20 patients Follow-up= 6 months Prospective evaluation	20 patients with unilateral lumbar radiculopathy	Autologous conditioned serum (ACS)	• Interlaminar injection with 2 mL of contrast followed by 2 mL of ACS • A maximum of 3 injections at 7 days interval were given based on the clinical response • 20 patients received number of injections ranging from 1 to 3	VAS, ODI	• There was significant improvement in pain relief and function with VAS improving from 6.95 to 2.0 and ODI improving from 27.9 to 8.5. • 5 patients (20%) had complications which were immediate and systematic rather than local and were of short duration lasting less than 30 minutes	• Positive results with injection of ACS with disease modifying course with reduction of pain and disability • Small sample size with injection of contrast, which may diminish the effect of ACS

Table 4 (cont.). *Summary of lumbar epidural injection PRP studies published to date*

Study Details	Population	Cell/Solution Type	Cell or Solution Dose and Delivery Pathway	Outcome Parameters	Results	Conclusion
Kirchner and Anitua, 2016 (92) Sample size=86 patients Follow-up = 6 months Observational retrospective pilot study	86 patients 47 females: age range 22 to 81, median age 58 39 males: age range 29 to 79 years, median age 55	86 patients each received one intradiscal, one intraarticular facet and one transforaminal epidural injection of plasma rich in growth factors	Transforaminal injection of 2 mL of activated PRGF after intradiscal injection of 4 mL of PRGF and facet joint infiltration	VAS	• At the end of the study (6 months), 90.7% of the patients showed an excellent score, 8.1% showed a moderate VAS score, and 1.2% of patients were included in the ineffective score group • There were no major adverse events	• Approximately 90% of the patients improved after 6 months • Positive study • Results are unreliable because of observational study and multiple injections into the disc, facet joint and with transforaminal application • Number of injections are unknown
Bhatia & Chopra, 2016 (98) Sample size=10 patients Follow-up=3 months Prospective evaluation	10 patients with findings of lumbar disc herniation/ prolapse in MRI, or either sex with age less than 65 years	Platelet-rich plasma	Interlaminar epidural injection with 2 mL of PRP	VAS and ODI	Patients who had received epidural injections of autologous PRP showed improvements in their scores of evaluation tools. Improvement was sustained during the 3 month study period and was not associated with any complications.	Autologous PRP can be considered as a good alternative to epidural steroids and surgery in management of patients with chronic prolapsed intervertebral disc.

ODI = Oswestry Disability Index; VAS =Visual Analog Scale; PRGF=platelet-rich growth factor; PRP=platelet-rich plasma

(96,97). The methodologic quality and risk of bias assessment of sacroiliac joint injections showed an RCT (95) of high quality based on the Cochrane review criteria and moderate quality based on IPM-QRB criteria as shown in Appendix Tables 4 and 5. Of the 2 observational studies (96,97), one was of moderate quality (96) and the second one was of low quality (97) as shown in Appendix Table 6.

Because of only a single RCT and a total of 3 studies (95-97), a metaanalysis could not be performed. Table 6 describes a summary of the studies of sacroiliac joint PRP injections.

2.7 Assessment of Evidence

Evidence was assessed for intradiscal injections, epidural injections, lumbar facet joint injections, and sacroiliac joint injections.

2.7.1 Intradiscal Injections

Evidence for intradiscal injections was based on the injected biological, either PRP or MSCs.

2.7.1.1 Platelet-Rich Plasma

Based on the available evidence, including one high-quality RCT (90) with multiple moderate-quality observational studies (80,81,89,91,92), a single-arm metaanalysis and evidence from a systematic review (60), the qualitative evidence is Level III (on a scale of Level I through V) using a qualitative modified approach to grading of evidence based on best-evidence synthesis.

2.7.1.2 Mesenchymal Stem Cells

Based on the available evidence with a high-quality RCT (85), multiple moderate-quality observational studies (62,77,83,84,86), a single-arm metaanalysis, and 2 systematic reviews (60,61), the qualitative evidence is Level III (on a scale of Level I through V) using a qualitative modified approach to grading of evidence based on best evidence synthesis.

Table 5. *Summary of lumbar facet joint PRP studies published to date.*

Study Details	Methods	Results	Conclusion
Wu et al, 2017 (94) Sample size=46 Follow-up=6 months Prospective randomized trial Chronic facet joint pain	46 patients with lumbar facet syndrome were randomized to intra-articular injections of PRP versus LA/corticosteroid Outcomes were assessed with VAS, ODI, and RMDQ	• Back pain improved in both groups immediately and at one month follow-up • At 3 months, back pain relief was superior in PRP injection group compared to steroid group • Functional status improvement was observed in both groups; however, at 3 months, there was significant improvement in PRP group compared to steroid group • Highest objective success rate with over 50% pain relief in 81% was found at 3 and 6 months after treatment, whereas highest success rate in 85% of the patients in the steroid group dissipated after one month	• There was significant improvement in both groups in short-term. However, improvement was long lasting for 6 months in PRP group • Positive study • Limited with a small number of patients
Wu et al, 2016 (93) Sample size=19 Follow-up=3 months Prospective clinical evaluation Chronic facet joint pain	19 patients with lumbar facet syndrome given intra-articular injections of PRP Outcomes were assessed with VAS, ODI, and RMDQ	• 79% of the patients reported satisfactory improvement with good or excellent at 3 month follow-up after injection of PRP • ODI and RMDQ were also significantly improved. There were no adverse events. A positive small study of intraarticular injection of autologous PRP	Positive results in a study with a small number of patients and relatively short follow-up of 3 months
Kirchner and Anitua, 2016 (92) Sample size=86 Follow-up = 6 months Observational retrospective pilot study, n=86 humans Facet Joint Syndrome	One intradiscal, one intra-articular facet, and one transforaminal epidural injection of PRGF under fluoroscopic guidance-control were carried out in 86 patients with chronic LBP.	VAS showed a statistically significant drop at 1, 3, and 6 months after the treatment ($P < 0.0001$) except for the pain reduction between the 3rd and 6th month whose signification was lower ($P < 0.05$).	• Positive study with multiple drawbacks with multiple injections in each setting with injection into disc, facet joint, and epidural space • Extremely high positive results in a low quality observational study

VAS=visual analog scale; ODI=Oswestry Disability Index; RMDQ=Roland Morris Disability Questionnaire; PRP=platelet-rich plasma; PRGF=platelet-rich growth factor; LBP=low back pain

2.7.2 Epidural Injections

Based on one high-quality RCT (101), multiple relevant moderate-quality observational studies (92,98-100) and a single-arm metaanalysis, the qualitative evidence is Level IV (on a scale of Level I through V) using a qualitative modified approach to grading of evidence based on best evidence synthesis.

2.7.3 Lumbar Facet Joint Injections

Based on one high-quality RCT (94) and 2 moderate-quality observational studies (92,93), the qualitative evidence for facet joint injections with PRP is Level IV (on a scale of Level I through V) using a qualitative modified approach to grading of evidence based on best evidence synthesis.

2.7.4 Sacroiliac Joint Injection

Based on one high-quality RCT (95), one moderate-quality observational study (96), and one low-quality case report (97), the qualitative evidence is Level IV (on a scale of Level I through V) using a qualitative modified approach to grading of evidence based on best evidence synthesis.

3.0 Discussion

This systematic review identified one RCT in each category of regenerative medicine for lumbosacral procedures (intradiscal injections with PRP or MSCs, lumbar epidural injections, lumbar facet joint injections, and sacroiliac joint injections). Single-arm metaanalysis for disc injections and epidural injections were included.

Table 6. *Summary of sacroiliac joint injection PRP studies published to date.*

Study Details	Methods	Results	Conclusion
Singla et al, 2017 (95) Sample size=40 Follow-up=3 months Prospective, randomized open blinded endpoint study Chronic low back pain with sacroiliac joint pathology	Patients were randomized into 2 groups with one group receiving 1.5 mL of methylprednisolone 40 mg/mL and 1.5 mL of 2% lidocaine with 0.5 mL of saline, whereas, PRP group receiving 3 mL of leukocyte free PRP with 0.5 mL of calcium chloride with ultrasound guided sacroiliac joint injection Outcomes were assessed with Visual Analog Scale (VAS) scores, Oswestry Disability Index (ODI), Short Form-12	• At 3-month follow-up, 90% of the patients reported satisfactory relief with PRP; whereas, satisfactory relief was observed in 25% of the patients receiving steroids. • A strong association was observed in patients receiving PRP and showing a reduction of VAS of greater than 50% from baseline	• Positive first prospective, randomized study • Small number of patients
Navani & Gupta, 2015 (96) Sample size=10 (4 males, 6 females) with sacroiliac joint pain of greater than 6 months duration Age Distribution=5 patients below 40 and 5 patients over 40 Sacroiliac joint pain	Sacroiliac joint injection under fluoroscopic guidance with PRP	• All patients improved 3 months post injection and maintained low pain levels not requiring any additional treatment up to 6 months post injection • SF-36 demonstrated improvement in both physical component summary scores and mental component summary scores in all patients • No adverse events	A positive case series of 10 patients
Ko et al, 2017 (97) Sample size=4 Follow-up=2 yrs. Case series	Sacroiliac joint injection with PRP under ultrasound Outcomes were assessed with Short form, McGill Pain Questionnaire, Numeric Rating Scale (NRS), Oswestry Disability Index (ODI)	• At 12-month follow-up there was marked improvement in joint stability, a statistically significant reduction in pain, and improvement in quality of life • The clinical benefits of PRP were still significant at 4 years post treatment	PRP showed long lasting positive results in this short case series of 4

PRP-platelet-rich plasma; SF-36= 36-item short form health survey;

The study demonstrated Level III (on a scale of Level I through V) evidence for intradiscal injections of PRP and MSCs, and Level IV (on a scale of Level I through V) evidence for epidural injections, lumbar facet joint injections, and sacroiliac joint injections based on qualitative evidence synthesis on a scale of Level I through V. There were no included studies of MSCs for epidural administration, lumbar facet joint injections, or sacroiliac joint injections.

This is the first systematic review assessing various therapeutic modalities of regenerative medicine inclusive of current analyses in the available literature. The results of the present investigation are comparable to those previously published for intradiscal injections (60,61); however, systematic reviews of epidural injections, facet joint injections and sacroiliac joint injections are not available.

Chronic low back pain is complex with involvement of the intervertebral discs, zygapophysial joints, and sacroiliac joints, all of which have been implicated as common causes based on studies using controlled diagnostic techniques. While the therapeutic role of regenerative medicine in discogenic pain is better established, the role of these therapies in epidural injections, facet joint injections and sacroiliac joint injections, though promising, is less clear. Degenerative disc disease and age-related debilitating disorders have a prevalence of more than 90% in people older than 50 years (102). Degenerative disc disease is a result of the combined effects of aging, adverse loading, dehydration, cellular apoptosis, and other imbalances in tissue metabolism (103). With reduction in matrix anabolism, there is an increased expression of prolonged-inflammatory cytokines and proteolytic enzymes (104). Disc degeneration involves changes in the composition of the extracellular matrix and loss of nucleus pulposus cells leading to morphological and functional abnormalities. The intervertebral disc is a dynamic structure having minimal vascu-

lar support and poor regenerative potential, especially after disruption of its metabolic homeostasis (105,106). Consequently, a potential therapeutic strategy involves augmenting the nucleus pulposus cell population in effort to restore the normal biologic function and matrix sufficiency. Currently the gold standard for treatment of intervertebral disc disease is fusion surgery using multiple techniques (6-8,107,108). The results of multiple analyses of the effectiveness of fusion procedures show that these types of surgery do not preserve the intervertebral disc, and they are not superior to other conservative modalities including epidural injections (109). Most conservative treatments based on physical therapy, injection therapy, or intradiscal therapies do not reverse the degenerative cascade (16,39-50,110-113). But because biological therapies offer the possibility of preventing or inhibiting degenerative changes of the intervertebral disc, they may represent a better treatment alternative (58,113,114). It has been postulated that the ideal interventional or biologic therapy should resolve nociceptive discogenic pain, slow or reverse the catabolic metabolism within the intervertebral disc environment and should provide partial or complete restoration of disc tissue (115).

The 12 studies included in our systematic review with single-arm meta-analysis included 2 high-quality RCTs (85,92), one using PRP (92) and the other using MSCs (85). These studies showed significant improvements in pain relief and functional status while demonstrating limited improvements in promoting regeneration and the reversal of degenerative processes. There has been significant activity in recent years with intensified efforts in the application of tissue engineering and regenerative medicine that have demonstrated effectiveness in preclinical studies (58,59). Preclinical research has been focused around 3 biological approaches to addressing the problem of degenerative disc disease - stimulation of anabolic processes, modulation of catabolic processes, and the provision of new cell growth in regeneration (116). Tissue-engineered cellular therapy has focused on chondrocytes (117), stem cell replacement therapy (118), and the injection of PRP. Biological approaches are appealing because of their minimal invasiveness and reduced costs in comparison to surgical interventions, including fusion. Based on the available literature, MSCs are known for their self-renewal ability as well as their capacity to sustain nearby cellular activity (119). Furthermore, they can differentiate into osteoblasts, adipocytes, chondroblasts, and cells with the phenotypic features of the intervertebral disc under proper in vitro conditions (120,121). MSCs may be derived from bone marrow, adipose, or umbilical cord tissue (122). At this time, there is limited literature evidence to determine which source of MSCs is superior (122). Some authors favor the use of adipose tissue because of its relatively higher concentration of MSCs, ease of harvesting, and its superior differentiation into the intervertebral disc phenotype (123,124). However, the capability of bone-marrow-derived MSCs to differentiate into nucleus-pulposus-like cells and their ability to stimulate production of new cell matrix when co-cultured (125) has also been described. In this regard, Mochida et al (82) tested this theory in intervertebral disc repair with activated nucleus pulposus cell transplantation over a 3-year prospective clinical study of its safety. Others investigators have also tested implantation of MSCs (62,77,83-86).

Some researchers have investigated the role of MSCs in healing and regeneration by studying autologous bone marrow MSC migration into the injured intervertebral disc. In a study of the homing process of MSCs, evidence was provided suggesting that although MSCs are recruited during disc degeneration, only a limited number of MSCs migrate to the intervertebral disc, presumably because of the disc's avascular nature (126). Wang et al (58) performed a systematic review and metaanalysis of using animal control trials to investigate the efficacy of intervertebral disc regeneration with stem cells. They demonstrated that stem cells, transplanted into the intervertebral disc in the quadruped animals, decelerate or arrest the intervertebral disc degenerative process. Yim et al (127), in a systematic review of comparative controlled studies regarding the potential benefits of using MSCs in disc degeneration, showed that all types of MSCs (bone marrow, adipose, or synovial tissue derived) demonstrated a significant inhibition of disc degeneration with a better quality of repair compared to non-MSC treatments. In addition, multiple in vitro and in vivo studies have demonstrated the effects of growth factors in regulating intervertebral disc cell proliferation and chondrogenic matrix metabolism (128). This suggests that the efficacy of intradiscal MSC injection could be enhanced by combining it with growth factors such as those found in PRP. Alternatively, PRP may be injected independently which produces similar results.

Platelet-rich plasma has been defined as a growth factors cocktail with the potential to promote nucleus pulposus cell differentiation and the reconstitution of human nucleus pulposus tissue (129-132). Among the

available literature, Chen et al (131) created an ex vivo porcine model of a degenerative intervertebral disc to test the regenerative ability of 3 different therapeutic regimens, including MSCs, PRP, and MSC/PRP combined treatments. Formica et al (132) in their assessment of preclinical studies on the role of PRP injection in intervertebral disc degeneration, included 6 in vitro and 6 in vivo studies. The included studies showed positive histological results along with MRI analysis and the in vivo studies highlighted the therapeutic effects of PRP. As shown in our assessment, 6 clinical studies have yielded positive results, demonstrating that PRP can be helpful when used alone, producing results similar to MSCs in terms of regeneration and cell proliferation (80,81,89-92,131).

The next most pressing area of investigation involves the role that epidural PRP or MSCs injection plays in the treatment of disc herniation, any associated radiculopathy, radiculopathy without disc herniation, and in other biochemical and mechanical disorders (16,17,133). The nucleus pulposus contains a variety of inflammatory pain mediators, including phospholipase A2, nitric oxide, and prostaglandin E. In addition, cytokines such as interleukin IL-1 have been identified as mediators of inflammatory and degenerative changes (15-18,60). It has been hypothesized that the disc material, with inflammatory substances, causes direct toxic injury to the nerve root by chemical mediation which subsequently amplifies intra- and extraneural inflammation. This results in venous congestion and conduction block (133,134). Of the multiple cytokines identified within the disc, IL-1 appears to be of special interest regarding its role in the causation of lower back pain (135). Strategies for inhibiting the biological activities of IL-1 include the use of IL-1 receptor antagonist (RA), soluble forms of IL-1 receptors, and type-1 cytokines such as IL-4, IL-10, and IL-13 that inhibit synthesis of IL-1 and/or increase the synthesis of IL-1ra (60). The therapeutic use of cytokine inhibitors and growth factors was proposed in the late 1970's and early 1980's (136). In fact, some of the proponents of epidural injections believe that epidural injections produce anti-inflammatory effects with or without the use of steroids (39,109,137,138) since the role of steroids in epidural injections for managing discogenic pain continues to be debated and remains controversial (138).

With significant developments in biologicals as an evolutionary model, PRP and its derivatives, along with MSCs, have been proposed for epidural administration. Autologous condition serum (ACS) preparations have been described as a source of anti-inflammatory cytokines, including IL-4, IL-10, IL-13, and IL-1ra and also contain elevated concentrations of growth factors like fibroblast growth factor (FGF-2), hepatocyte growth factor (HGF), and transforming growth factor beta (TGF-β1) (135). ACS contains high concentrations of IL-1ra, an antagonist to IL-1 that is a "biochemical sensitizer" of nerve roots in radiculopathy (100,101,139). Consequently, ACS has been considered as a promising new treatment option for patients with radicular pain. ACS has been studied in one RCT (101) and in a prospective assessment (100). Similarly, the epidural injection of PRP with its multiple growth factors has also been studied (98). In addition, multiple other innovations including plasma lysate (99) and plasma rich in growth factors (PRGF-Endoret) (92) have been studied for epidural use. However, the literature has been tainted with flawed studies providing inadequate evidence. Despite this, present single arm metaanalysis did show moderate results with Level IV (on a scale of Level I through V) evidence using epidural injections of PRP or its derivatives.

Results of lumbar facet and sacroiliac intraarticular injections of biologics have demonstrated similar outcomes as those seen in the use of biologics for peripheral joints (140-144). The literature reports a significant increase in the levels of pro-inflammatory cytokines such as growth related oncogene-a (GRO-a), soluble intercellular adhesion molecule-1 (sICAM-1), interferon-c (IFN-c), tumor necrosis factor-a (TNF-a), interleukin (IL)-1b, IL-6, and IL-17 (94,145,146). Because of its high concentration of activated growth factors and cytokines including platelet-derived growth factor (PDGF), TGF-β, fibroblast growth factor (FGF), insulin-like growth factor 1 (IGF-1), connective tissue growth factor (CTGF), and epidermal growth factor (EGF), as well as bioactive proteins, PRP has been used to promote the healing of tendons, ligaments, muscle, and bone (94,148,149). These elements within PRP act as humoral mediators to induce an anti-inflammatory effect and to facilitate the natural healing cascade by promoting cell proliferation, migration and differentiation, protein transcription, extracellular matrix regeneration, angiogenesis, and collagen synthesis (94,150-153). Based on this evidence, some investigators have recommended PRP as the most appropriate option for the treatment of lumbar facet joint syndrome. Three clinical studies have been presented which assessed the role of PRP injection into the facet joints and included one RCT (92-94); however, there are no studies evaluating the role of MSCs injections into the facet joints. The effectiveness of PRP use

in sacroiliac joint pain was also evaluated in 3 studies which included one RCT as well as 2 case reports (95-97). However, there are no studies exploring the role of MSCs in sacroiliac joint treatment.

This systematic review has multiple advantages in comparison with the existing studies, as it is the largest of its nature thus far, and it includes epidural injections, lumbar facet joint injections, and sacroiliac joint injections of biologicals. Due to limitations, this review utilized a single-arm metaanalysis to evaluate the effect of biologics from baseline through treatment.

This review has several limitations. Despite extensive search criteria and inclusion of databases and trials, only 21 studies met our inclusion criteria and were incorporated into in this systematic review and metaanalysis. While this appears to be a robust number, after apportioning based on the treatment and type of injection, the number of studies was reduced to 6 for intradiscal PRP injections (80,81,89-92), 6 for intradiscal MSCs (62,77,83-86), 5 for epidural injections (92,98-101), 3 for lumbar facet joint injections (92-94), and 3 for sacroiliac joint injections (95-97). In addition, the majority of these studies were observational studies and case reports with significant heterogeneity and were performed on only a small number of patients. Other disadvantages include lack of valid or reliable selection criteria for the patients with discogenic pain. Further, there are no significant reports on quality of content of injectate, technical and other complications of discography, and diffusion or bulk flow of injectate to site of inflammation. Finally, there is no data reporting on clinically meaningful results and we have virtually no data reporting on clinically meaningful results, whereas we have some data on statistically meaningful results.

4.0 Conclusion

The findings of this systematic review and single-arm meta-analysis demonstrate that MSCs and PRP may be effective in managing discogenic low back pain, radicular pain, facet joint pain, and sacroiliac joint pain, with variable levels of evidence. The evidence is Level III (on a scale of Level I through V) for intradiscal injections versus Level IV (on a scale of Level I through V) evidence for epidural, facet joint, and sacroiliac joint injections. More studies are warranted to better understand the role of MSCs and PRP in mediating or modulating beneficial effects in low back related pain.

Acknowledgments

The authors wish to thank Tonie M. Hatton and Diane E. Neihoff, transcriptionists, for their assistance in preparation of this manuscript. We would like to thank the editorial board of Pain Physician for review and criticism in improving the manuscript.

Author Affiliation

Dr. Sanapati, Pre-Intern, University Pain Medicine and Rehabilitation Center, Department of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical School. Dr. Manchikanti is Medical Director of the Pain Management Center of Paducah, Paducah, KY, and Clinical Professor, Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY, and Professor of Anesthesiology-Research, Department of Anesthesiology, School of Medicine, LSU Health Sciences Center, New Orleans, LA. Dr. Atluri is Medical Director, Tri-State Spine Care Institute, Cincinnati, OH. Dr. Jordan is a Neurologist at the Neurological Associates of West Los Angeles, the Interventional Group, Santa Monica, CA, and UCLA Department of Neurology, Los Angeles, CA. Dr. Albers is Director of Research, Radiology Research and Consultation, Sacramento, CA.Dr. Pappolla is Medical Director, St. Michael's Pain and Spine Clinics, Houston, TX, and Professor of Neurology, Univeristy of Texas Medical Branch, Galveston, TX. Dr. Kaye is Professor, Program Director, and Chair, Department of Anesthesiology, and Professor, Department of Pharmacology, LSU Health Science Center, New Orleans, LA. Dr. Candido is Professor and Chair, Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL, and Professor of Clinical Anesthesiology and Surgery, University of Illinois College of Medicine, Chicago. Vidyasagar Pampati is a Statistician at the Pain Management Center of Paducah, Paducah, KY. Dr. Hirsch is Vice Chair and Service Line Chief of Interventional Radiology, Chief of NeuroInterventional Spine, Director Interventional Neuroradiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.

Appendix

Appendix Table 1

Appendix Table 2

Appendix Table 3

Appendix Table 4

Appendix Table 5

Appendix Table 6

Appendix Table 7

Appendix Table 8

Appendix Tables 9 to 11

To view pdf with Appendix links active, visit
Pain Physician journal website
to access manuscript pdf.

References

1. Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C, Williams G, Smith E, Vos T, Barendregt J, Murray C, Burstein R, Buchbinder R. The global burden of low back pain: Estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis* 2014; 73:968-974.
2. U.S. Burden of Disease Collaborators. The state of US health, 1990 – 2010: Burden of diseases, injuries, and risk factors. *JAMA* 2013; 310:591-608.
3. Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, Hamavid H, Horst C, Johnson EK, Joseph J, Lavado R, Lomsadze L, Reynolds A, Squires E, Campbell M, DeCenso B, Dicker D, Flaxman AD, Gabert R, Highfill T, Naghavi M, Nightingale N, Templin T, Tobias MI, Vos T, Murray CJ. US spending on personal health care and public health, 1996 – 2013. *JAMA* 2016; 316:2627-2646.
4. Dieleman JL, Squires E, Bui AL, Campbell M, Chapin A, Hamavid H, Horst C, Li Z, Matyasz T, Reynolds A, Sadat N, Schneider MT, Murray CJL. Factors associated with increase in US health care spending, 1996-2013. *JAMA* 2017; 318:1668-1678.
5. Manchikanti L, Soin A, Mann DP, Bakshi S, Pampati V, Hirsch JA. Reversal of growth of utilization of interventional techniques in managing chronic pain in Medicare population post Affordable Care Act. *Pain Physician* 2017; 20:551-567.
6. Rajaee SS, Bae HW, Kanim LE, Delamarter RB. Spinal fusion in the United States: Analysis of trends from 1998 to 2008. *Spine (Phila Pa 1976)* 2012; 37:67-76.
7. Bae HW, Rajaee SS, Kanim LE. Nationwide trends in the surgical management of lumbar spinal stenosis. *Spine (Phila Pa 1976)* 2013; 38:916-926.
8. Kim CH, Chung CK, Park CS, Choi B, Kim MJ, Park BJ. Reoperation rate after surgery for lumbar herniated intervertebral disc disease: nationwide cohort study. *Spine (Phila Pa 1976)* 2013; 38:581-590.
9. Manchikanti L, Abdi S, Atluri S, Benyamin RM, Boswell MV, Buenaventura RM, Bryce DA, Burks PA, Caraway DL, Calodney AK, Cash KA, Christo PJ, Cohen SP, Colson J, Conn A, Cordner HJ, Coubarous S, Datta S, Deer TR, Diwan SA, Falco FJE, Fellows B, Geffert SC, Grider JS, Gupta S, Hameed H, Hameed M, Hansen H, Helm II S, Janata JW, Justiz R, Kaye AD, Lee M, Manchikanti KN, McManus CD, Onyewu O, Parr AT, Patel VB, Racz GB, Sehgal N, Sharma M, Simopoulos TT, Singh V, Smith HS, Snook LT, Swicegood J, Vallejo R, Ward SP, Wargo BW, Zhu J, Hirsch JA. An update of comprehensive evidence-based guidelines for interventional techniques of chronic spinal pain: Part II: Guidance and recommendations. *Pain Physician* 2013; 16:S49-S283.
10. Manchikanti L, Kaye AM, Knezevic NN, McAnally H, Trescot AM, Blank S, Pampati V, Abdi S, Grider JS, Kaye AD, Manchikanti KN, Cordner HJ, Gharibo CG, Harned ME, Albers SL, Atluri S, Aydin SM, Bakshi S, Barkin R, Benyamin RM, Boswell MV, Buenaventura RM, Calodney AK, Cedeno DL, Datta S, Deer TR, Fellows B, Galan V, Grami V, Hansen H, Helm S 2nd, Justiz R, Koyyalagunta D, Malla Y, Navani A, Nouri K, Pasupuleti R, Sehgal N, Silverman SM, Simopoulos TT, Singh V, Slavin KV, Solanki DR, Staats PS, Vallejo R, Wargo BW, Watanabe A, Hirsch JA. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. *Pain Physician* 2017: 20:2S:S3-S92.
11. Manchikanti L, Helm S 2nd, Benyamin RM, Hirsch JA. A critical analysis of Obamacare: Affordable care or insurance for many and coverage for few? *Pain Physician* 2017; 20:111-138.
12. Obama B. United States health care reform: Progress to date and next steps. *JAMA* 2016; 316:525-532.
13. Manchikanti L, Soin A, Benyamin RM, Singh V, Falco FJ, Calodney AK, Grami V, Hirsch JA. An update of the systematic appraisal of the accuracy and utility of discography in chronic spinal pain. *Pain Physician* 2018; 21:91-110.
14. Manchikanti L, Hirsch JA, Falco FJ, Boswell MV. Management of lumbar zygapophysial (facet) joint pain. *World J Orthop* 2016; 7:315-337.
15. Simopoulos TT, Manchikanti L, Gupta S, Aydin SM, Kim CH, Solanki D, Nampiaparampil DE, Singh V, Staats PS, Hirsch JA. Systematic review of the diagnostic accuracy and therapeutic effectiveness of sacroiliac joint interventions. *Pain Physician* 2015; 18:E713-E756.
16. Manchikanti L, Hirsch JA. An update on the management of chronic lumbar discogenic pain. *Pain Manag* 2015; 5:373-386.
17. Manchikanti L, Hirsch JA. Clinical management of radicular pain. *Expert Rev Neurother* 2015; 17:681-693.
18. Bogduk N, Aprill C, Derby R. Lumbar discogenic pain: State-of-the-art review. *Pain Med* 2013; 14:813-836.
19. Hancock MJ, Maher CG, Latimer J, Spindler MF, McAuley JH, Laslett M, Bogduk N. Systematic review of tests to identify the disc, SIJ or facet joint as the source of low back pain. *Eur Spine J* 2007; 16:1539-1550.
20. Manchikanti L, Albers SL, Hirsh JA, Boswell, MV. Lumbar Disk Herniation. In: Kaye AD, ed. Scientific American Pain Management. Hamilton: Decker; September 2017. DOI: 10.2310/7900.15047. www.DeckerIP.com
21. Savettieri G, Salemi G, Rocca WA, Meneghini F, D'Arpa A, Morgante L, Coraci MA, Reggio A, Grigoletto F, Di Perri R. Prevalence of lumbosacral radiculopathy in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. *Acta Neurol Scand* 1996; 93:464-469.
22. Califf RM, Robb MA, Bindman AB, Briggs JP, Collins FS, Conway PH, Coster TS, Cunningham FE, De Lew N, DeSalvo KB, Dymek C, Dzau VJ, Fleurence RL, Frank RG, Gaziano JM, Kaufmann P, Lauer M, Marks PW, McGinnis JM, Richards C, Selby JV, Shulkin DJ, Shuren J, Slavitt AM, Smith SR, Washington BV, White PJ, Woodcock J, Woodson J, Sherman RE. Transforming Evidence Generation to Support Health and Health Care Decisions. *N Engl J Med* 2016; 375:2395-2400.
23. Manchikanti L, Kaye AD, Hirsch JA. Proposed Medicare physician payment schedule for 2017: Impact on interventional pain management practices. *Pain Physician* 2016; 19:E935-E955.
24. Manchikanti L, Singh V, Hirsch JA. Facility payments for interventional pain management procedures: Impact of proposed rules. *Pain Physician* 2016; 19:E957-E984.
25. Manchikanti L, Hammer M, Benyamin RM, Hirsch JA. Physician Quality Reporting System (PQRS) for interventional pain management practices: Challenges and opportunities. *Pain Physician* 2016; 19:E15-E32.

26. Hirsch JA, Harvey HB, Barr RM, Donovan WD, Duszak R Jr, Nicola GN, Schaefer PW, Manchikanti L. Sustainable growth rate repealed, MACRA revealed: Historical context and analysis of recent changes in Medicare physician payment methodologies. *AJNR Am J Neuroradiol* 2016; 37:210-214.
27. Hirsch JA, Leslie-Mazwi TM, Barr RM, McGinty G, Nicola GN, Patel AB, Manchikanti L. The Burwell roadmap. *J Neurointerv Surg* 2016; 8:544-546.
28. Slavitt A. Our next health care debate. *JAMA* 2017; 318:1212-1213.
29. Hirsch JA, Leslie-Mazwi TM, Nicola GN, Bhargavan-Chatfield M, Seidenwurm DJ, Silva E, Manchikanti L. PQRS and the MACRA: Value-based payments have moved from concept to reality. *AJNR Am J Neuroradiol* 2016; 37:2195-2200.
30. Manchikanti L, Helm S 2nd, Benyamin RM, Hirsch JA. Merit-Based Incentive Payment System (MIPS): Harsh choices for interventional pain management physicians. *Pain Physician* 2016; 19:E917-E934.
31. Hirsch JA, Leslie-Mazwi TM, Patel AB, Rabinov JD, Gonzalez RG, Barr RM, Nicola GN, Klucznik RP, Prestigiacomo CJ, Manchikanti L. MACRA: Background, opportunities and challenges for the neurointerventional specialist. *J Neurointerv Surg* 2016; 8:868-874.
32. Leavitt SB. NSAID dangers may limit pain-relief options. Pain-Topics News/ Research UPDATES, March 14, 2010.
http://updates.pain-topics.org/2010/03/nsaid-dangers-may-limit-pain-relief.html.
33. Moore A, Wiffen P, Kalso E. Antiepileptic drugs for neuropathic pain and fibromyalgia. *JAMA* 2014; 312:182-183.
34. Pannell WC, Savin DD, Scott TP, Wang JC, Daubs MD. Trends in the surgical treatment of lumbar spine disease in the United States. *Spine J* 2015; 15:1719-1727.
35. Manchikanti L, Pampati V, Hirsch JA. Utilization of interventional techniques in managing chronic pain in Medicare population from 2000 to 2014: An analysis of patterns of utilization. *Pain Physician* 2016; 19:E531-E546.
36. Manchikanti L, Soin A, Mann DP, Bakshi S, Pampati V, Hirsch JA. Reversal of growth of utilization of interventional techniques in managing chronic pain in Medicare population post Affordable Care Act. *Pain Physician* 2017; 20:551-567.
37. Manchikanti L, Hirsch JA, Pampati V, Boswell MV. Utilization of facet joint and sacroiliac joint interventions in Medicare population from 2000 to 2014: Explosive growth continues! *Curr Pain Headache Rep* 2016; 20:58.
38. Manchikanti L, Pampati V, Hirsch JA. Retrospective cohort study of usage patterns of epidural injections for spinal pain in the US fee-for-service Medicare population from 2000 to 2014. *BMJ Open* 2016; 6:e013042.
39. Manchikanti L, Knezevic NN, Boswell MV, Kaye AD, Hirsch JA. Epidural injections for lumbar radiculopathy and spinal stenosis: A comparative systematic review and meta-analysis. *Pain Physician* 2016; 19:E365-E410.
40. Manchikanti L, Manchikanti KN, Gharibo CG, Kaye AD. Efficacy of percutaneous adhesiolysis in the treatment of lumbar post surgery syndrome. *Anesth Pain Med* 2016; 6:e26172.
41. Grider JS, Manchikanti L, Carayannopoulos A, Sharma ML, Balog CC, Harned ME, Grami V, Justiz R, Nouri KH, Hayek SM, Vallejo R, Christo PJ. Effectiveness of spinal cord stimulation in chronic spinal pain: A systematic review. *Pain Physician* 2016; 19:E33-E54.
42. Chou R, Hashimoto R, Friedly J, Fu R, Dana T, Elliott S, Sullivan S, Jarvik J. Pain management injection therapies for low back pain. Technology Assessment Report Prepared for Agency for Healthcare Research and Quality (AHRQ). Project ID: ESIB0813. October 29, 2014.
43. Manchikanti L, Falco FJE, Pampati V, Cash KA, Benyamin RM, Hirsch JA. Cost utility analysis of caudal epidural injections in the treatment of lumbar disc herniation, axial or discogenic low back pain, central spinal stenosis, and post lumbar surgery syndrome. *Pain Physician* 2013; 16:E129-E143.
44. Manchikanti L, Helm S II, Pampati V, Racz GB. Cost utility analysis of percutaneous adhesiolysis in managing pain of post-lumbar surgery syndrome and lumbar central spinal stenosis. *Pain Pract* 2015; 15:414-422.
45. Helm II S, Racz GB, Gerdesmeyer L, Justiz L, Hayek SM, Kaplan ED, El Terany MA, Knezevic NN. Percutaneous and endoscopic adhesiolysis in managing low back and lower extremity pain: A systematic review and meta-analysis. *Pain Physician* 2016; 19:E245-E282.
46. Manchikanti L, Pampati V, Benyamin RM, Hirsch JA. Cost utility analysis of lumbar interlaminar epidural injections in the treatment of lumbar disc herniation, central spinal stenosis, and axial or discogenic low back pain. *Pain Physician* 2017; 20:219-228.
47. Manchikanti L, Pampati V, Kaye AD, Hirsch JA. Cost-utility analysis of cervical therapeutic medial branch blocks in managing chronic neck pain. *Int J Med Sci* 2017; 14:1307-1316.
48. Manchikanti L, Pampati V, Kaye AD, Hirsch JA. Therapeutic lumbar facet joint nerve blocks in the treatment of chronic low back pain: Cost utility analysis based on a randomized controlled trial. *Korean J Pain* 2018; 31:27-38.
49. Taylor RS, Ryan J, O'Donnell R, Eldabe S, Kumar K, North RB. The cost-effectiveness of spinal cord stimulation in the treatment of failed back surgery syndrome. *Clin J Pain* 2010; 26:463-469.
50. Farber SH, Han JL, Elsamadicy AA, Hussaini Q, Yang S, Pagadala P, Parente B, Xie J, Lad SP. Long-term cost utility of spinal cord stimulation in patients with failed back surgery syndrome. *Pain Physician* 2017; 20:E797-E805.
51. Xiaochuan L, Zhong CF, Tang JH, Liang RW, Luo SJ, Huang CM. The effectiveness and safety of selective lumbar decompression in diagnostic doubt patients: A retrospective control study. *Pain Physician* 2017; 20:E541-E550.
52. Cheng J, Chen SL, Zimmerman N, Dalton JE, LaSalle G, Rosenquist R. A new radiofrequency ablation procedure to treat sacroiliac joint pain. *Pain Physician* 2016; 19:603-615.
53. Dengler JD, Kools D, Pflugmacher R, Gasbarrini A, Prestamburgo D, Gaetani P, van Eeckhoven E, Cher D, Sturesson B. 1-Year results of a randomized controlled trial of conservative management vs. minimally invasive surgical treatment for sacroiliac joint pain. *Pain Physician* 2017; 20:537-550.
54. Hegarty D. Clinical outcome following radiofrequency denervation for refractory sacroiliac joint dysfunction using the Simplicity III Probe: A 12-month retrospective evaluation. *Pain Physician* 2016; 19:E129-E135.
55. Miguélez-Rivera L, Pérez-Castrillo S, González-Fernández ML, Prieto-Fernández JG, López-González ME, García-Cosamalón J, Villar-Suárez V. Immunomodulation of mesenchymal stem cells in discogenic pain. *Spine J* 2018; 18:330-342.

56. Caplan AI. Mesenchymal stem cells: Time to change the name! *Stem Cells Transl Med* 2017; 6:1445-1451.
57. Vadalà G, Russo F, Ambrosio L, Loppini M, Denaro V. Stem cells sources for intervertebral disc regeneration. *World J Stem Cells* 2016; 8:185-201.
58. Wang Z, Perez-Terzic CM, Smith J, Mauck WD, Shelerud RA, Maus TP, Yang TH, Murad MH, Gou S, Terry MJ, Dauffenbach JP, Pingree MJ, Eldrige JS, Mohammed K, Benkhadra K, van Wijnen AJ, Qu W. Efficacy of intervertebral disc regeneration with stem cells—A systematic review and meta-analysis of animal controlled trials. *Gene* 2015; 564:1-8.
59. Khan S, Mafi P, Mafi R, Khan W. A systematic review of mesenchymal stem cells in spinal cord injury, intervertebral disc repair and spinal fusion. *Curr Stem Cell Res Ther* 2018; 13:316-323.
60. Basso M, Cavagnaro L, Zanirato A, Divano S, Formica C, Formica M, Felli L. What is the clinical evidence on regenerative medicine in intervertebral disc degeneration? *Musculoskelet Surg* 2017; 101:93-104.
61. Wu T, Song HX, Dong Y, Li JH. Cell-based therapies for lumbar discogenic low back pain: Systematic review and single-arm meta-analysis. Spine *(Phila Pa 1976)* 2018; 43:49-57.
62. Meisel HJ, Ganey T, Hutton WC, Libera J, Minkus Y, Alasevic O. Clinical experience in cell-based therapeutics: Intervention and outcome. *Eur Spine J* 2006; 15:S397-S405.
63. LaPrade RF, Dragoo JL, Koh JL, Murray IR, Geeslin AG, Chu CR. AAOS research symposium updates and consensus: Biologic treatment of orthopaedic injuries. *J Am Acad Orthop Surg* 2016; 24:e62-e78.
64. Viganò M, Sansone V, d'Agostino MC, Romeo P, Perucca Orfei C, de Girolamo L. Mesenchymal stem cells as therapeutic target of biophysical stimulation for the treatment of musculoskeletal disorders. *J Orthop Surg Res* 2016; 11:163.
65. Bashir J, Sherman A, Lee H, Kaplan L, Hare JM. Mesenchymal stem cell therapies in the treatment of musculoskeletal diseases. *PM R* 2014; 6:61-69.
66. Navani A, Li G, Chrystal J. Platelet rich plasma in musculoskeletal pathology: A necessary rescue or a lost cause? *Pain Physician* 2017; 20:E345-E356.
67. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). http://prisma-statement.org/
68. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. *Ann Intern Med* 2009; 151:W65-W94.
69. A Measurement Tool to Assess systematic Reviews (*AMSTAR*). https://amstar.ca/
70. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017; 358:j4008.
71. Furlan AD, Malmivaara A, Chou R, Maher CG, Deyo RA, Schoene M, Bronfort G, van Tulder MW; Editorial Board of the Cochrane Back, Neck Group. 2015 Updated Method Guideline for Systematic Reviews in the Cochrane Back and Neck Group. *Spine (Phila Pa 1976)* 2015; 40:1660-1673.
72. Manchikanti L, Hirsch JA, Cohen SP, Heavner JE, Falco FJE, Diwan S, Boswell MV, Candido KD, Onyewu O, Zhu J, Sehgal N, Kaye AD, Benyamin RM, Helm II S, Singh V, Datta S, Abdi S, Christo PJ, Hameed H, Hameed M, Vallejo R, Pampati V, Racz GB, Raj PP. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument. *Pain Physician* 2014; 17:E263-E290.
73. Manchikanti L, Hirsch JA, Heavner JE, Cohen SP, Benyamin RM, Sehgal N, Falco FJE, Vallejo R, Onyewu O, Zhu J, Kaye AD, Boswell MV, Helm II S, Candido KD, Diwan S, Simopoulos TT, Singh V, Pampati V, Racz GB, Raj PP. Development of an interventional pain management specific instrument for methodologic quality assessment of nonrandomized studies of interventional techniques. *Pain Physician* 2014; 17:E291-E317.
74. Manchikanti L, Falco FJE, Benyamin RM, Kaye AD, Boswell MV, Hirsch JA. A modified approach to grading of evidence. *Pain Physician* 2014; 17:E319-E325.
75. Jeong H, Yim HW, Cho YS, Kim YI, Jeong SN, Kim HB, Oh IH. Efficacy and safety of stem cell therapies for patients with stroke: A systematic review and single arm meta-analysis. *Int J Stem Cells* 2014; 7:63-69.
76. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? *Psychol Methods* 2006; 11:193-206.
77. Pettine KA, Suzuki RK, Sand TT, Murphy MB. Autologous bone marrow concentrate intradiscal injection for the treatment of degenerative disc disease with three-year follow-up. *Int Orthop* 2017; 41:2097-2103.
78. Pettine K, Suzuki R, Sand T, Murphy M. Treatment of discogenic back pain with autologous bone marrow concentrate injection with minimum two year follow-up. *Int Orthop* 2016; 40:135-140.
79. Pettine KA, Murphy MB, Suzuki RK, Sand TT. Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. *Stem Cells* 2015; 33:146-156.
80. Navani A, Ambach MA, Navani R, Wei J. Biologics and lumbar discogenic pain: 18 month follow-up for safety and efficacy. *IPM Reports* 2018; 2:111-118.
81. Levi D, Horn S, Tyszko S, Levin J, Hecht-Leavitt C, Walko E. Intradiscal platelet-rich plasma injection for chronic discogenic low back pain: Preliminary results from a prospective trial. *Pain Med*2016; 17:1010-1022.
82. Mochida J, Sakai D, Nakamura Y, Watanabe T, Yamamoto Y, Kato S. Intervertebral disc repair with activated nucleus pulposus cell transplantation: A three-year, prospective clinical study of its safety. *Eur Cell Mater* 2015; 29: 202-212.
83. Coric D, Pettine K, Sumich A, Boltes MO. Prospective study of disc repair with allogeneic chondrocytes presented at the 2012 Joint Spine Section Meeting. *J Neurosurg Spine* 2013; 18:85-95.
84. Orozco L, Soler R, Morera C, Alberca M, Sánchez A, García-Sancho J.. Intervertebral disc repair by autologous mesenchymal bone marrow cells: A pilot study. *Transplantation* 2011; 92:822-828.
85. Noriega DC, Ardura F, Hernández-Ramajo R, Martín-Ferrero MÁ, Sánchez-Lite I, Toribio B, Alberca M, García V, Moraleda JM, Sánchez A, García-Sancho J. Intervertebral disc repair by allogeneic mesenchymal bone marrow cells: A randomized controlled trial. *Transplantation* 2017; 101:1945-1951.

86. Kumar H, Ha DH, Lee EJ, Park JH, Shim JH, Ahn TK, Kim KT, Ropper AE, Sohn S, Kim CH, Thakor DK, Lee SH, Han IB. Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study. *Stem Cell Res Ther* 2017 15; 8:262.
87. Pang X, Yang H, Peng B. Human umbilical cord mesenchymal stem cell transplantation for the treatment of chronic discogenic low back pain. *Pain Physician* 2014; 17:E525-E530.
88. Yoshikawa T, Ueda Y, Miyazaki K, Koizumi M, Takakura Y. Disc regeneration therapy using marrow mesenchymal cell transplantation: A report of two case studies. *Spine (Phila Pa 1976)* 2010; 35:E475-E480.
89. Monfett M, Harrison J, Boachie-Adjei K, Lutz G. Intradiscal platelet-rich plasma (PRP) injections for discogenic low back pain: An update. *Int Orthop* 2016; 40:1321-1328.
90. Tuakli-Wosornu YA, Terry A, Boachie-Adjei K, Harrison JR, Gribbin CK, LaSalle EE, Nguyen JT, Solomon JL, Lutz GE. Lumbar intradiskal platelet-rich plasma (PRP) injections: A prospective, double-blind, randomized controlled study. *PM R* 2016; 8:1-10.
91. Akeda K, Ohishi K, Masuda K, Bae WC, Takegami N, Yamada J, Nakamura T, Sakakibara T, Kasai Y, Sudo A. Intradiscal injection of autologous platelet-rich plasma releasate to treat discogenic low back pain: A preliminary clinical trial. *Asian Spine J* 2017; 11:380-389.
92. Kirchner F, Anitua E. Intradiscal and intra-articular facet infiltrations with plasma rich in growth factors reduce pain in patients with chronic low back pain. *J Craniovertebr Junction Spine* 2016; 7:250-256.
93. Wu J, Du Z, Lv Y, Zhang J, Xiong W, Wang R, Liu R, Zhang G, Liu Q. A new technique for the treatment of lumbar facet joint syndrome using intra-articular injection with autologous platelet rich plasma. *Pain Physician* 2016; 19:617-625.
94. Wu J, Zhou J, Liu C, Zhang J, Xiong W, Lv Y, Liu R, Wang R, Du Z, Zhang G, Liu Q. A prospective study comparing platelet-rich plasma and local anesthetic (LA)/corticosteroid in intra-articular injection for the treatment of lumbar facet joint syndrome. *Pain Pract* 2017; 17:914-924.
95. Singla V, Batra YK, Bharti N, Goni VG, Marwaha N. Steroid vs. platelet-rich plasma in ultrasound-guided sacroiliac joint injection for chronic low back pain. *Pain Pract* 2017; 17:782-791.
96. Navani A, Gupta D. Role of intra-articular platelet-rich plasma in sacroiliac joint pain. *Tech Reg Anesth Pain Manage* 2015; 19:54-59.
97. Ko GD, Mindra S, Lawson GE, Whitmore S, Arseneau L. Case series of ultrasound-guided platelet-rich plasma injections for sacroiliac joint dysfunction. *J Back Musculoskelet Rehabil* 2017; 30:363-370.
98. Bhatia R, Chopra G. Efficacy of platelet rich plasma via lumbar epidural route in chronic prolapsed intervertebral disc patients-A pilot study. *J Clin Diagn Res* 2016; 10:UC05-UC07.
99. Centeno C, Markle J, Dodson E, Stemper I, Hyzy M, Williams C, Freeman M. The use of lumbar epidural injection of platelet lysate for treatment of radicular pain. *J Exp Orthop* 2017; 4:38.
100. Kumar R, Goni VG, Batra YK. Autologous conditioned serum as a novel alternative option in the treatment of unilateral lumbar radiculopathy: A prospective study. *Asian Spine J* 2015; 9:916-922.
101. Becker C, Heidersdorf S, Drewlo S, de Rodriguez SZ, Krämer J, Willburger RE. Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blind, reference-controlled study. *Spine (Phila Pa 1976)* 2007; 32:1803-1808.
102. Teraguchi M, Yoshimura N, Hashizume H, Muraki S, Yamada H, Minamide A, Oka H, Ishimoto Y, Nagata K, Kagotani R, Takiguchi N, Akune T, Kawaguchi H, Nakamura K, Yoshida M. Prevalence and distribution of intervertebral disc degeneration over the entire spine in a population-based cohort: the Wakayama Spine Study. *Osteoarthritis Cartilage* 2014; 22:104-110.
103. Liebscher T, Haefeli M, Wuertz K, Nerlich AG, Boos N. Age-related variation in cell density of human lumbar intervertebral disc. *Spine (Phila Pa 1976)* 2011;36:153-159.
104. Marks PH, Donaldson ML. Inflammatory cytokine profiles associated with chondral damage in the anterior cruciate ligament deficient knee. *Arthroscopy* 2005; 21:1342-1347.
105. Peng B, Wu W, Hou S, Li P, Zhang C, Yang Y. The pathogenesis of discogenic low back pain. *J Bone Joint Surg Br* 2005; 87:62-67.
106. Formica M, Basso M, Cavagnaro L, Formica C, Zanirato A, Felli L. Kümmell disease: Illustrative case for definition criteria. *Spine J* 2016; 16:e707-e708.
107. Formica M, Berjano P, Cavagnaro L, Zanirato A, Piazzolla A, Formica C. Extreme lateral approach to the spine in degenerative and post traumatic lumbar diseases: Selection process, results and complications. *Eur Spine J* 2014; 23:684-692.
108. Allain J, Delecrin J, Beaurain J, Poignard A, Vila T, Flouzat-Lachaniette CH. Stand-alone ALIF with integrated intracorporeal anchoring plates in the treatment of degenerative lumbar disc disease: A prospective study on 65 cases. *Eur Spine J* 2014; 23:2136-2143.
109. Manchikanti L, Staats PS, Nampiaparampil DE, Hirsch JA. What is the role of epidural injections in the treatment of lumbar discogenic pain: A systematic review of comparative analysis with fusion and disc arthroplasty. *Korean J Pain* 2015; 28:75-87.
110. Helm S 2nd, Simopoulos TT, Stojanovic MP, Abdi S, El Terany MA. Effectiveness of thermal annular procedures in treating discogenic low back pain. *Pain Physician* 2017; 20:447-470.
111. Cavagnaro L, Basso M, Mazzola MA, Formica M Lumbar Traction in the management of low back pain: A survey of latest results. *J Nov Physiother* 2014; 4:231
112. Wegner I, Widyahening IS, van Tulder MW, Blomberg SE, de Vet HC, Brønfort G, Bouter LM, van der Heijden GJ. Traction for low-back pain with or without sciatica. *Cochrane Database Syst Rev* 2013; 8:CD003010.
113. Pimentel DC, El Abd O, Benyamin RM, Buehler AM, Leite VF, Mazloomdoost D, Chen J, Hsing WT, Amadera JE. Anti-tumor necrosis factor antagonists in the treatment of low back pain and radiculopathy: A systematic review and meta-analysis. *Pain Physician* 2014; 17:E27-E44.
114. Di Martino A, Merlini L, Faldini C. Autoimmunity in intervertebral disc herniation: From bench to bedside. *Expert Opin Ther Targets* 2013; 17:1461-1470.
115. Depalma M. Biologic treatments for

discogenic low back pain. *SpineLine* 2012; 13:19-23.

116. Benneker LM, Andersson G, Iatridis JC, Sakai D, Härtl R, Ito K, Grad S. Cell therapy for intervertebral disc repair: advancing cell therapy from bench to clinics. *Eur Cell Mater* 2014; 27:5-11.
117. Acosta FL Jr, Metz L, Adkisson HD, Liu J, Carruthers-Liebenberg E, Milliman C, Maloney M, Lotz JC. Porcine intervertebral disc repair using allogeneic juvenile articular chondrocytes or mesenchymal stem cells. *Tissue Eng Part A* 2011; 17:3045-3055.
118. Wuertz K, Godburn K, Neidlinger-Wilke C, Urban J, Iatridis JC. Behavior of mesenchymal stem cells in the chemical microenvironment of the intervertebral disc. *Spine (Phila Pa 1976)* 2008; 33:1843-1849.
119. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; 8:315-317.
120. Alini M, Roughley PJ, Antoniou J, Stoll T, Aebi M. A biological approach to treating disc degeneration: not for today, but maybe for tomorrow. *Eur Spine J* 2002; 11:S215–S220.
121. Mafi R, Hindocha S, Mafi P, Griffin M, Khan WS. Sources of adult mesenchymal stem cells applicable for musculoskeletal applications—a systematic review of the literature. *Open Orthop J* 2011; 5:242-248.
122. Sobajima S, Vadala G, Shimer A, Kim JS, Gilbertson LG, Kang JD. Feasibility of a stem cell therapy for intervertebral disc degeneration. *Spine J* 2008; 8:888-896.
123. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. *Circ Res* 2007; 100:1249-1260.
124. Longo UG, Papapietro N, Petrillo S, Franceschetti E, Maffulli N, Denaro V. Mesenchymal stem cell for prevention and management of intervertebral disc degeneration. *Stem Cells Int* 2012; 2012:921053.
125. Strassburg S, Richardson SM, Freemont AJ, Hoyland JA. Co-culture induces mesenchymal stem cell differentiation and modulation of the degenerate human nucleus pulposus cell phenotype. *Regen Med* 2010; 5:701-711.
126. Sakai D, Nishimura K, Tanaka M, Nakajima D, Grad S, Alini M, Kawada H, Ando K, Mochida J. Migration of bone marrow- derived cells for endogenous repair in a new tail-looping disc degeneration model in the mouse: A pilot study. *Spine J* 2015; 15:1356-1365.
127. Yim RL, Lee JT, Bow CH, Meij B, Leung V, Cheung KM, Vavken P, Samartzis D. A systematic review of the safety and efficacy of mesenchymal stem cells for disc degeneration: Insights and future directions for regenerative therapeutics. *Stem Cells Dev* 2014; 23:2553-2567.
128. Masuda K, Oegema TR, An HS. Growth factors and treatment of intervertebral disc degeneration. *Spine (Phila Pa 1976)* 2004; 29:2757-2769.
129. Marx RE. Platelet-rich plasma (PRP): What is PRP and what is not PRP? *Implant Dent* 2001; 10:225-228.
130. Akeda K, An HS, Pichika R, Attawia M, Thonar EJ, Lenz ME, Uchida A, Masuda K. Platelet-rich plasma (PRP) stimulates the extracellular matrix metabolism of porcine nucleus pulposus and anulus fibrosus cells cultured in alginate beads. *Spine (Phila Pa 1976)* 2006; 31:959-966.
131. Chen WH, Liu HY, Lo WC, Wu SC, Chi CH, Chang HY, Hsiao SH, Wu CH, Chiu WT, Chen BJ, Deng WP. Intervertebral disc regeneration in an ex vivo culture system using mesenchymal stem cells and platelet-rich plasma. *Biomaterials* 2009; 30:5523-5533.
132. Formica M, Cavagnaro L, Formica C, Mastrogiacomo M, Basso M, Di Martino A. What is the preclinical evidence on platelet rich plasma and intervertebral disc degeneration? *Eur Spine J* 2015; 24:2377-2386.
133. Spangfort EV. The lumbar disc herniation: a computer-aided analysis of 2,504 operations. *Acta Orthop Scand Suppl* 1972; 142:1-95.
134. Saal JA. Natural history and nonoperative treatment of lumbar disc herniation. *Spine (Phila Pa 1976)* 1996; 21:2S-9S.
135. Wright-Carpenter T, Klein P, Schaferhoff P, Appell HJ, Mir LM, Wehling P. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. *Int J Sports Med* 2004; 25:588-593.
136. Mooney V, Saal JA, Saal JS. Evaluation and treatment of low back pain. *Clin Symp* 1996; 48:1-32.
137. Bogduk N. Epidural steroids. *Spine (Phila Pa 1976)* 1995; 20:845-848.
138. Shanthanna H, Busse JW, Thabane L, Paul J, Couban R, Choudhary H, Kaushal A, Suzumura E, Kim I, Harsha P. Local anesthetic injections with or without steroid for chronic non-cancer pain: a protocol for a systematic review and meta-analysis of randomized controlled trials. *Syst Rev* 2016; 5:18.
139. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. *Am J Vet Res* 2007; 68:290-296.
140. Zhao L, Kaye AD, Abd-Elsayed A. Stem cells for the treatment of knee osteoarthritis: a comprehensive review. *Pain Physician* 2018; 21:229-242.
141. Chakravarthy K, Chen Y, He C, Christo PJ. Stem Cell Therapy for Chronic Pain Management: Review of Uses, Advances, and Adverse Effects. *Pain Physician* 2017; 20:293-305.
142. Lai LP, Stitik TP, Foye PM, Georgy JS, Patibanda V, Chen B. Use of platelet-rich plasma in intra-articular knee injections for osteoarthritis: A systematic review. *PM R* 2015; 7:637-648.
143. Khoshbin A, Leroux T, Wasserstein D, Marks P, Theodoropoulos J, Ogilvie-Harris D, Gandhi R, Takhar K, Lum G, Chahal J. The efficacy of platelet-rich plasma in the treatment of symptomatic knee osteoarthritis: A systematic review with quantitative synthesis. *Arthroscopy* 2013; 29):2037-2048.
144. Rodríguez-Merchán EC. Intra-articular injections of mesenchymal stem cells for knee osteoarthritis. *Am J Orthop (Belle Mead NJ)* 2014; 43:E282-E291.
145. Igarashi A, Kikuchi S, Konno S, Olmarker K. Inflammatory cytokines released from the facet joint tissue in degenerative lumbar spinal disorders. *Spine (Phila Pa 1976)* 2004; 29:2091-2095.
146. Kim JS, Ali MH, Wydra F, Li X, Hamilton JL, An HS, Cs-Szabo G, Andrews S, Moric M, Xiao G, Wang JH, Chen D, Cavanaugh JM, Im HJ. Characterization of degenerative human facet joints and facet joint capsular tissues. *Osteoarthritis Cartilage* 2015; 23:2242-2251.
147. Polly DW, Cher DJ, Wine KD, Whang PG, Frank CJ, Harvey CF, Lockstadt H, Glaser JA, Limoni RP, Sembrano

JN; INSITE Study Group. Randomized controlled trial of minimally invasive sacroiliac joint fusion using triangular titanium implants vs nonsurgical management for sacroiliac joint dysfunction: 12-month outcomes. *Neurosurgery* 2015; 77:674-690; discussion 690-691.

148. Kabiri A, Esfandiari E, Esmaeili A, Hashemibeni B, Pourazar A, Mardani M. Platelet-rich plasma application in chondrogenesis. *Adv Biomed Res* 2014;3: 138.
149. Yadav R, Kothari SY, Borah D. Comparison of local injection of platelet rich plasma and corticosteroids in the treatment of lateral epicondylitis of humerus. *J Clin Diagn Res* 2015; 9:Rc05–Rc07.
150. Meheux CJ, McCulloch PC, Lintner DM, Varner KE, Harris JD. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: A systematic review. *Arthroscopy* 2016; 32:495-505.
151. Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P, Desiderio MA. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: Mechanisms of NF-kappaB inhibition via HGF. *J Cell Physiol* 2010; 225:757-766.
152. Mazzocca AD, McCarthy MB, Intravia J, Beitzel K, Apostolakos J, Cote MP, Bradley J, Arciero RA. An in vitro evaluation of the anti-inflammatory effects of platelet rich plasma, ketorolac, and methylprednisolone. *Arthroscopy* 2013; 29:675-683.
153. Campbell KA, Saltzman BM, Mascarenhas R, Khair MM, Verma NN, Bach BR Jr, Cole BJ. Does intra-articular platelet-rich plasma injection provide clinically superior outcomes compared with other therapies in the treatment of knee osteoarthritis? A systematic review of overlapping meta-analyses. *Arthroscopy* 2015; 31:2213-2221.

Appendix Table 1. Sources of risk of bias and Cochrane Review rating system.

Bias Domain	Source of Bias		Possible Answers
Selection	(1) Was the method of randomization adequate?	A random (unpredictable) assignment sequence. Examples of adequate methods are coin toss (for studies with 2 groups), rolling a dice (for studies with 2 or more groups), drawing of balls of different colors, drawing of ballots with the study group labels from a dark bag, computer-generated random sequence, preordered sealed envelopes, sequentially-ordered vials, telephone call to a central office, and preordered list of treatment assignments.	Yes/No/ Unsure
		Examples of inadequate methods are: alternation, birth date, social insurance/security number, date in which they are invited to participate in the study, and hospital registration number.	
Selection	(2) Was the treatment allocation concealed?	Assignment generated by an independent person not responsible for determining the eligibility of the patients. This person has no information about the persons included in the trial and has no influence on the assignment sequence or on the decision about eligibility of the patient.	Yes/No/ Unsure
Performance	(3) Was the patient blinded to the intervention?	Index and control groups are indistinguishable for the patients or if the success of blinding was tested among the patients and it was successful.	Yes/No/ Unsure
Performance	(4) Was the care provider blinded to the intervention?	Index and control groups are indistinguishable for the care providers or if the success of blinding was tested among the care providers and it was successful.	Yes/No/ Unsure
Detection	(5) Was the outcome assessor blinded to the intervention?	Adequacy of blinding should be assessed for each primary outcome separately. This item should be scored "yes" if the success of blinding was tested among the outcome assessors and it was successful or:	Yes/No/ Unsure
		* for patient-reported outcomes in which the patient is the outcome assessor (e.g., pain, disability): the blinding procedure is adequate for outcome assessors if participant blinding is scored "yes"	
		* for outcome criteria assessed during scheduled visit and that supposes a contact between participants and outcome assessors (e.g., clinical examination): the blinding procedure is adequate if patients are blinded, and the treatment or adverse effects of the treatment cannot be noticed during clinical examination	
		* for outcome criteria that do not suppose a contact with participants (e.g., radiography, magnetic resonance imaging): the blinding procedure is adequate if the treatment or adverse effects of the treatment cannot be noticed when assessing the main outcome	
		* for outcome criteria that are clinical or therapeutic events that will be determined by the interaction between patients and care providers (e.g., cointerventions, hospitalization length, treatment failure), in which the care provider is the outcome assessor: the blinding procedure is adequate for outcome assessors if item "4" (caregivers) is scored "yes"	
		* for outcome criteria that are assessed from data of the medical forms: the blinding procedure is adequate if the treatment or adverse effects of the treatment cannot be noticed on the extracted data	
Attrition	(6) Was the drop-out rate described and acceptable?	The number of participants who were included in the study but did not complete the observation period or were not included in the analysis must be described and reasons given. If the percentage of withdrawals and drop-outs does not exceed 20% for short-term follow-up and 30% for long-term follow-up and does not lead to substantial bias a "yes" is scored. (N.B. these percentages are arbitrary, not supported by literature).	Yes/No/ Unsure
Attrition	(7) Were all randomized participants analyzed in the group to which they were allocated?	All randomized patients are reported/analyzed in the group they were allocated to by randomization for the most important moments of effect measurement (minus missing values) irrespective of noncompliance and cointerventions.	Yes/No/ Unsure

Appendix Table 1 (cont.). Sources of risk of bias and Cochrane Review rating system.

Bias Domain	Source of Bias		Possible Answers
Reporting	(8) Are reports of the study free of suggestion of selective outcome reporting?	All the results from all prespecified outcomes have been adequately reported in the published report of the trial. This information is either obtained by comparing the protocol and the report, or in the absence of the protocol, assessing that the published report includes enough information to make this judgment.	Yes/No/ Unsure
Selection	(9) Were the groups similar at baseline regarding the most important prognostic indicators?	Groups have to be similar at baseline regarding demographic factors, duration and severity of complaints, percentage of patients with neurological symptoms, and value of main outcome measure(s).	Yes/No/ Unsure
Performance	(10) Were cointerventions avoided or similar?	If there were no cointerventions or they were similar between the index and control groups.	Yes/No/ Unsure
Performance	(11) Was the compliance acceptable in all groups?	The reviewer determines if the compliance with the interventions is acceptable, based on the reported intensity, duration, number and frequency of sessions for both the index intervention and control intervention(s). For example, physiotherapy treatment is usually administered for several sessions; therefore it is necessary to assess how many sessions each patient attended. For single-session interventions (e.g., surgery), this item is irrelevant.	Yes/No/ Unsure
Detection	(12) Was the timing of the outcome assessment similar in all groups?	Timing of outcome assessment should be identical for all intervention groups and for all primary outcome measures.	Yes/No/ Unsure
Other	(13) Are other sources of potential bias unlikely?	Other types of biases. For example: * When the outcome measures were not valid. There should be evidence from a previous or present scientific study that the primary outcome can be considered valid in the context of the present. * Industry-sponsored trials. The conflict of interest (COI) statement should explicitly state that the researchers have had full possession of the trial process from planning to reporting without funders with potential COI having any possibility to interfere in the process. If, for example, the statistical analyses have been done by a funder with a potential COI, usually "unsure" is scored.	Yes/No/ Unsure

Source: Furlan AD, Malmivaara A, Chou R, Maher CG, Deyo RA, Schoene M, Bronfort G, van Tulder MW; Editorial Board of the Cochrane Back, Neck Group. 2015 Updated Method Guideline for Systematic Reviews in the Cochrane Back and Neck Group. Spine (Phila Pa 1976) 2015; 40:1660-1673 (71).

Appendix Table 2. Item checklist for assessment of randomized controlled trials of IPM techniques utilizing IPM – QRB.

		Scoring
I.	TRIAL DESIGN AND GUIDANCE REPORTING	
1.	CONSORT or SPIRIT	
	Trial designed and reported without any guidance	0
	Trial designed and reported utilizing minimum criteria other than CONSORT or SPIRIT criteria or trial was conducted prior to 2005	1
	Trial implies it was based on CONSORT or SPIRIT without clear description with moderately significant criteria for randomized trials or the trial was conducted before 2005	2
	Explicit use of CONSORT or SPIRIT with identification of criteria or trial conducted with high level reporting and criteria or conducted before 2005	3
II.	DESIGN FACTORS	
2.	Type and Design of Trial	
	Poorly designed control group (quasi selection, convenient sampling)	0
	Proper active-control or sham procedure with injection of active agent	2
	Proper placebo control (no active solutions into active structures)	3
3.	Setting/Physician	
	General setting with no specialty affiliation and general physician	0
	Specialty of anesthesia/PMR/neurology/radiology/ortho, etc.	1
	Interventional pain management with interventional pain management physician	2
4.	Imaging	
	Blind procedures	0
	Ultrasound	1
	CT	2
	Fluoro	3
5.	Sample Size	
	Less than 50 participants in the study without appropriate sample size determination	0
	Sample size calculation with less than 25 patients in each group	1
	Appropriate sample size calculation with at least 25 patients in each group	2
	Appropriate sample size calculation with 50 patients in each group	3
6.	Statistical Methodology	
	None or inappropriate	0
	Appropriate	1
III.	PATIENT FACTORS	
7.	Inclusiveness of Population	
7a.	For epidural procedures:	
	Poorly identified mixed population	0
	Clearly identified mixed population	1
	Disorders specific trials (i.e. well defined spinal stenosis and disc herniation, disorder specific, disc herniation or spinal stenosis or post surgery syndrome)	2
7b.	For facet or sacroiliac joint interventions:	
	No diagnostic blocks	0
	Selection with single diagnostic blocks	1
	Selection with placebo or dual diagnostic blocks	2
8.	Duration of Pain	
	Less than 3 months	0

Appendix Table 2 (cont.). Item checklist for assessment of randomized controlled trials of IPM techniques utilizing IPM – QRB.

		Scoring
	3 to 6 months	1
	> 6 months	2
9.	Previous Treatments	
	Conservative management including drug therapy, exercise therapy, physical therapy, etc.	
	Were not utilized	0
	Were utilized sporadically in some patients	1
	Were utilized in all patients	2
10.	Duration of Follow-up with Appropriate Interventions	
	Less than 3 months or 12 weeks for epidural or facet joint procedures, etc. and 6 months for intradiscal procedures and implantables	0
	3 to 6 months for epidural or facet joint procedures, etc., or 1 year for intradiscal procedures or implantables	1
	6 months to 17 months for epidurals or facet joint procedures, etc., and 2 years or longer for discal procedures and implantables	2
	18 months or longer for epidurals and facet joint procedures, etc., or 5 years or longer for discal procedures and implantables	3
IV.	OUTCOMES	
11.	Outcomes Assessment Criteria for Significant Improvement	
	No descriptions of outcomes OR < 20% change in pain rating or functional status	0
	Pain rating with a decrease of 2 or more points or more than 20% reduction OR functional status improvement of more than 20%	1
	Pain rating with decrease of ≥ 2 points AND ≥ 20% change or functional status improvement of ≥ 20%	2
	Pain rating with a decrease of 3 or more points or more than 50% reduction OR functional status improvement with a 50% or 40% reduction in disability score	2
	Significant improvement with pain and function ≥ 50% or 3 points and 40% reduction in disability scores	4
12.	Analysis of all Randomized Participants in the Groups	
	Not performed	0
	Performed without intent-to-treat analysis without inclusion of all randomized participants	1
	All participants included with or without intent-to-treat analysis	2
13.	Description of Drop Out Rate	
	No description of dropouts, despite reporting of incomplete data or ≥ 20% withdrawal	0
	Less than 20% withdrawal in one year in any group	1
	Less than 30% withdrawal at 2 years in any group	2
14.	Similarity of Groups at Baseline for Important Prognostic Indicators	
	Groups dissimilar with significant influence on outcomes with or without appropriate randomization and allocation	0
	Groups dissimilar without influence on outcomes despite appropriate randomization and allocation	1
	Groups similar with appropriate randomization and allocation	2
15.	Role of Co-Interventions	
	Co-interventions were provided but were not similar in the majority of participants	0
	No co-interventions or similar co-interventions were provided in the majority of the participants	1
V.	RANDOMIZATION	
16.	Method of Randomization	

Appendix Table 2 (cont.). Item checklist for assessment of randomized controlled trials of IPM techniques utilizing IPM – QRB.

		Scoring
	Quasi randomized or poorly randomized or not described	0
	Adequate randomization (coin toss, drawing of balls of different colors, drawing of ballots)	1
	High quality randomization (Computer generated random sequence, pre-ordered sealed envelopes, sequentially ordered vials, telephone call, pre-ordered list of treatment assignments, etc.)	2
VI.	ALLOCATION CONCEALMENT	
17.	Concealed Treatment Allocation	
	Poor concealment of allocation (open enrollment) or inadequate description of concealment	0
	Concealment of allocation with borderline or good description of the process with probability of failure of concealment	1
	High quality concealment with strict controls (independent assignment without influence on the assignment sequence)	2
VII.	BLINDING	
18.	Patient Blinding	
	Patients not blinded	0
	Patients blinded adequately	1
19.	Care Provider Blinding	
	Care provider not blinded	0
	Care provider blinded adequately	1
20.	Outcome Assessor Blinding	
	Outcome assessor not blinded or was able to identify the groups	0
	Performed by a blinded independent assessor with inability to identify the assignment-based provider intervention (i.e., subcutaneous injection, intramuscular distant injection, difference in preparation or equipment use, numbness and weakness, etc.)	1
VIII.	CONFLICTS OF INTEREST	
21.	Funding and Sponsorship	
	Trial included industry employees	-3
	Industry employees involved; high levels of funding with remunerations by industry or an organization funded with conflicts	-3
	Industry or organizational funding with reimbursement of expenses with some involvement	0
	Industry or organization funding of expenses without involvement	1
	Funding by internal resources only with supporting entity unrelated to industry	2
	Governmental funding without conflict such as NIH, NHS, AHRQ	3
22.	Conflicts of Interest	
	None disclosed with potential implied conflict	0
	Marginally disclosed with potential conflict	1
	Well disclosed with minor conflicts	2
	Well disclosed with no conflicts	3
	Hidden conflicts with poor disclosure	–1
	Misleading disclosure with conflicts	–2
	Major impact related to conflicts	–3
TOTAL		48

Appendix Table 3. IPM checklist for assessment of nonrandomized or observational studies of IPM techniques utilizing IPM-QRBNR.

I.	STUDY DESIGN AND GUIDANCE REPORTING	Scoring
1.	STROBE or TREND Guidance	
	Case Report/Case Series	0
	Study designed without any guidance	1
	Study designed with minimal criteria and reporting with or without guidance	2
	Study designed with moderately significant criteria or implies it was based on STROBE or TREND without clear description or the study was conducted before 2011 or similar criteria utilized with study conducted before 2011	3
	Designed with high level criteria or explicitly uses STROBE or TREND with identification of criteria or conducted prior to 2011	4
II.	DESIGN FACTORS	
2.	Study Design and Type	
	Case report or series (uncontrolled – longitudinal)	0
	Retrospective cohort or cross-sectional study	1
	Prospective cohort case-control study	2
	Prospective case control study	3
	Prospective, controlled, nonrandomized	4
3.	Setting/Physician	
	General setting with no specialty affiliation and general physician	0
	Specialty of anesthesia/PMR/neurology, etc.	1
	Interventional pain management with interventional pain management physician	2
4.	Imaging	
	Blind procedures	0
	Ultrasound	1
	CT	2
	Fluoro	3
5.	Sample Size	
	Less than 100 participants without appropriate sample size determination	0
	At least 100 participants in the study without appropriate sample size determination	1
	Sample size calculation with less than 50 patients in each group	2
	Appropriate sample size calculation with at least 50 patients in each group	3
	Appropriate sample size calculation with 100 patients in each group	4
6.	Statistical Methodology	
	None	0
	Some statistics	1
	Appropriate	2
III.	PATIENT FACTORS	
7.	Inclusiveness of Population	
7a.	For epidural procedures:	
	Poorly identified mixed population	1
	Poorly identified mixed population with large sample (≥ 200)	2
	Clearly identified mixed population	3
	Disorders specific trials (i.e. well defined spinal stenosis and disc herniation, disorder specific, disc herniation or spinal stenosis or post surgery syndrome)	4
7b.	For facet or sacroiliac joint interventions:	
	No specific selection criteria	1
	No diagnostic blocks based on clinical symptomatology	2

Appendix Table 3 (cont.). IPM checklist for assessment of nonrandomized or observational studies of IPM techniques utilizing IPM-QRBNR.

	Selection with single diagnostic blocks	3
	Selection with placebo or dual diagnostic blocks	4
8.	Duration of Pain	
	Less than 3 months	0
	3 to 6 months	1
	> 6 months	2
9.	Previous Treatments	
	Conservative management including drug therapy, exercise therapy, physical therapy, etc.	
	Were not utilized	0
	Were utilized sporadically in some patients	1
	Were utilized in all patients	2
10.	Duration of Follow-up with Appropriate Interventions	
	Less than 3 months or less for epidural or facet joint procedures, etc., and 6 months for intradiscal procedures and implantables	1
	3-6 months for epidural or facet joint procedures, etc., or one year for intradiscal procedures or implantables	2
	6-12 months for epidurals or facet joint procedures, etc., and 2 years or longer for discal procedures and implantables	3
	18 months or longer for epidurals and facet joint procedures, etc., or 5 years or longer for discal procedures and implantables	4
IV.	OUTCOMES	
11.	Outcomes Assessment Criteria for Significant Improvement	
	No descriptions of outcomes OR < 20% change in pain rating or functional status	0
	Pain rating with a decrease of 2 or more points or more than 20% reduction OR functional status improvement of more than 20%	1
	Pain rating with decrease of ≥ 2 points AND ≥ 20% change or functional status improvement of ≥ 20%	2
	Pain rating with a decrease of 3 or more points or more than 50% reduction OR functional status improvement with a 50% or 40% reduction in disability score	2
	Significant improvement with pain and function ≥ 50% or 3 points and 40% reduction in disability scores	4
12.	Description of Drop Out Rate	
	No description despite reporting of incomplete data or more than 30% withdrawal	0
	Less than 30% withdrawal in one year in any group	1
	Less than 40% withdrawal at 2 years in any group	2
13.	Similarity of Groups at Baseline for Important Prognostic Indicators	
	No groups or groups dissimilar with significant influence on outcomes	0
	Groups dissimilar without significant influence on outcomes	1
	Groups similar	2
14.	Role of Co-Interventions	
	Dissimilar co-interventions or similar co-interventions in some of the participants	1
	No co-interventions or similar co-interventions in majority of the participants	2
V.	ASSIGNMENT	
15.	Method of Assignment of Participants	
	Case report/case series or selective assignment based on outcomes or retrospective evaluation based on clinical criteria	1

Appendix Table 3 (cont.). IPM checklist for assessment of nonrandomized or observational studies of IPM techniques utilizing IPM-QRBNR.

	Prospective study with inclusion without specific criteria	2
	Retrospective method with inclusion of all participants or random selection of retrospective data	3
	Prospective, well-defined assignment of methodology and inclusion criteria (quasi randomization, matching, stratification, etc.)	4
VI.	CONFLICTS OF INTEREST	
16.	Funding and Sponsorship	
	Trial included industry employees with or without proper disclosure	-3
	Industry employees involved; high levels of funding with remunerations by industry or an organization funded with conflicts	-3
	Industry or organizational funding with reimbursement of expenses with some involvement or no information available	0
	Industry or organization funding of expenses without involvement	1
	Funding by internal resources only	2
	Governmental funding without conflict such as NIH, NHS, AHRQ	3
TOTAL MAXIMUM		48

Source: Manchikanti L, et al. Development of an interventional pain management specific instrument for methodologic quality assessment of nonrandomized studies of interventional techniques. Pain Physician 2014; 17:E291-E317 (73).

Appendix Table 4. Methodological quality assessment of randomized trials utilizing Cochrane review criteria.

	Tuakli-Wosornu et al (90)	Becker et al (101)	Wu et al (94)	Singla et al (95)	Noriega et al (85)
Randomization adequate	Y	Y	Y	Y	Y
Concealed treatment allocation	Y	Y	Y	Y	Y
Patient blinded	Y	Y	Y	Y	Y
Care provider blinded	Y	N	Y	N	N
Outcome assessor blinded	Y	Y	Y	Y	Y
Drop-out rate described	Y	Y	Y	Y	Y
All randomized participants analyzed in the group	Y	Y	Y	Y	Y
Reports of the study free of suggestion of selective outcome reporting	Y	Y	Y	Y	Y
Groups similar at baseline regarding most important prognostic indicators	Y	Y	Y	Y	Y
Co-interventions avoided or similar	Y	Y	Y	Y	Y
Compliance acceptable in all group	Y	Y	Y	Y	Y
Time of outcome assessment in all groups similar	Y	Y	Y	Y	Y
Are other sources of potential bias likely	Y	Y	Y	Y	Y
Score	13/13	12/13	13/13	12/13	12/13

Y = Yes; N = No; U = Unclear

Source: Furlan AD, Malmivaara A, Chou R, Maher CG, Deyo RA, Schoene M, Bronfort G, van Tulder MW; Editorial Board of the Cochrane Back, Neck Group. 2015 Updated Method Guideline for Systematic Reviews in the Cochrane Back and Neck Group. Spine (Phila Pa 1976) 2015; 40:1660-1673 (71).

Appendix Table 5. Methodologic quality assessment of randomized trials utilizing IPM – QRB

		Tuakli-Wosornu et al (90)	Becker et al (101)	Wu et al (94)	Singla et al (95)	Noriega et al (85)
I.	TRIAL DESIGN AND GUIDANCE REPORTING					
1.	CONSORT or SPIRIT	0	0	0	0	0
II.	DESIGN FACTORS					
2.	Type and Design of Trial	3	2	2	2	3
3.	Setting/Physician	3	2	3	3	1
4.	Imaging	3	3	3	1	3
5.	Sample Size	2	2	2	1	0
6.	Statistical Methodology	1	2	1	1	1
III.	PATIENT FACTORS					
7.	Inclusiveness of Population	2	2	2	2	2
8.	Duration of Pain	2	2	2	2	2
9.	Previous Treatments	2	2	2	2	2
10.	Duration of Follow-up with Appropriate Interventions	2	2	1	0	2
IV.	OUTCOMES					
11.	Outcomes Assessment Criteria for Significant Improvement	2	2	4	1	4
12.	Analysis of all Randomized Participants in the Groups	2	2	2	2	2
13.	Description of Drop Out Rate	1	1	1	1	1
14.	Similarity of Groups at Baseline for Important Prognostic Indicators	2	2	2	2	2
15.	Role of Co-Interventions	1	1	1	1	1
V.	RANDOMIZATION					
16.	Method of Randomization	2	2	2	2	2
VI.	ALLOCATION CONCEALMENT					
17.	Concealed Treatment Allocation	2	2	2	2	2
VII.	BLINDING					
18.	Patient Blinding	1	2	1	1	1
19.	Care Provider Blinding	1	0	0	0	0
20.	Outcome Assessor Blinding	1	2	1	1	0
VIII.	CONFLICTS OF INTEREST					
21.	Funding and Sponsorship	0	2	0	0	3
22.	Conflicts of Interest	2	2	2	2	0
TOTAL		37	39	36	29	34

Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument. Pain Physician 2014; 17:E263-E290 (72).

Appendix Table 6. IPM checklist for assessment of nonrandomized or observational studies meeting inclusion criteria utilizing IPM - QRBNR.

		Pettine et al (77-79)	Navani et al (80)	Levi et al (81)	Coric et al (83)	Orozco et al (84)	Meisel et al (62)	Kumar et al (86)	Monfett et al (89)
I.	STUDY DESIGN AND GUIDANCE REPORTING								
1.	STROBE or TREND GUIDANCE	3	1	3	1	2	1	2	1
II.	DESIGN FACTORS								
2.	Study Design and Type	2	1	1	1	1	1	2	1
3.	Setting/Physician	2	3	2	2	2	2	2	2
4.	Imaging	3	3	3	3	3	3	3	3
5.	Sample Size	0	0	0	0	0	0	0	0
6.	Statistical Methodology	2	0	0	0	0	0	0	0
III.	PATIENT FACTORS								
7.	Inclusiveness of Population	4	4	4	4	4	4	4	4
8.	Duration of Pain	2	2	2	2	2	2	2	2
9.	Previous Treatments	2	2	2	2	2	2	2	2
10.	Duration of Follow-up with Appropriate Interventions	4	2	2	3	3	4	3	4
IV.	OUTCOMES								
11.	Outcomes Assessment Criteria for Significant Improvement	2	2	2	0	0	0	2	0
12.	Description of Drop Out Rate	2	2	2	2	2	2	2	2
13.	Similarity of Groups at Baseline for Important Prognostic Indicators	0	0	0	0	0	0	0	0
14.	Role of Co-Interventions	2	2	2	2	2	2	2	2
V.	ASSIGNMENT								
15.	Method of Assignment of Participants	0	0	0	0	0	0	0	0
VI.	CONFLICTS OF INTEREST								
16.	Funding and Sponsorship	1	2	1	1	1	1	1	0
TOTAL		31	26	26	23	24	24	27	23

Manchikanti L, et al. Development of an interventional pain management specific instrument for methodologic quality assessment of nonrandomized studies of interventional techniques. Pain Physician 2014; 17:E291-E317 (73).

Appendix Table 6 (cont.). IPM checklist for assessment of nonrandomized or observational studies of IPM techniques utilizing IPM - QRBNR.

		Akeda et al (91)	Kirchner & Anitua (92)	Wu et al (93)	Navani & Gupta (96)	Ko et al (97)	Bhatia & Chopra (98)	Centeno et al (99)	Kumar et al (100)
I.	STUDY DESIGN AND GUIDANCE REPORTING								
1.	STROBE or TREND GUIDANCE	1	2	2	1	0	2	1	2
II.	DESIGN FACTORS								
2.	Study Design and Type	1	1	2	1	0	2	2	1
3.	Setting/Physician	2	2	2	3	1	3	3	2
4.	Imaging	3	3	3	3	1	3	3	3
5.	Sample Size	0	0	0	0	0	0	0	0
6.	Statistical Methodology	2	2	2	0	0	0	2	2
III.	PATIENT FACTORS								
7.	Inclusiveness of Population	2	4	4	4	1	0	2	2
8.	Duration of Pain	1	2	2	2	2	2	2	2
9.	Previous Treatments	2	2	2	2	2	2	2	2
10.	Duration of Follow-up with Appropriate Interventions	2	3	1	2	0	0	0	2
IV.	OUTCOMES								
11.	Outcomes Assessment Criteria for Significant Improvement	0	2	2	2	2	0	1	1
12.	Description of Drop Out Rate	2	2	2	2	2	2	2	2
13.	Similarity of Groups at Baseline for Important Prognostic Indicators	0	0	0	0	0	0	0	0
14.	Role of Co-Interventions	2	2	2	2	2	2	2	2
V.	ASSIGNMENT								
15.	Method of Assignment of Participants	0	0	0	0	0	0	0	0
VI.	CONFLICTS OF INTEREST								
16.	Funding and Sponsorship	2	2	2	2	2	2	2	2
TOTAL		22	29	28	26	15	20	24	26

Source: Manchikanti L, et al. Development of an interventional pain management specific instrument for methodologic quality assessment of nonrandomized studies of interventional techniques. Pain Physician 2014; 17:E291-E317 (73).

Appendix Table 7. Descriptive data of numerical rating scale and visual analog scale (0-100) of PRP injections of lumbar disc.

STUDY DETAILS	N	Baseline	4 wk	8 wk/3 mon.	6 mon.	12 mon.
Akeda et al, 2017 (91)	14	75 ± 13	31 ± 2.5	32 + 20	32 ± 24	29 + 28 (9)
Monfett et al, 2016 (89)	29	79.8 ± 1.56	64.1 ± 18.5	58.2 ± 23.3	63.2 ± 21.2	57.9 ± 21.7
Navani et al, 2018 (80)	14	56.4 ± 13.51	43.21 ± 21.08	23.4 ± 13.6	16.3 ± 13.68	13.2 ± 8.5
Kirchner and Anitua, 2016 (92)	86	84 ± 11	40 ± 26	17 ± 23	8 + 17	--
Levi et al, 2016 (81)	22	65.9 ± 13.2	44.7 ± 2 2.6	42.1 ± 24.9	39.3 ± 26.0	--
Tuakli-Wosornu et al, 2016 (90)	29	79.8 ± 15.6	64.1 ± 18.8	58.2 ± 23.3	--	--

Appendix Table 8. Studies of cell therapy in discogenic pain with average NRS or VAS (Mean ± SD) at different points.

Study Name	n	Base	3 months	6 months	12 months	Difference in means from 12 months to Baseline (mean ± SE)
Coric et al, 2013 (83)	15	57	35	38	31	-22.33 ±1.03 $
Kumar et al, 2017 (86)	10	65 ± 12.7	43 ± 1.63	32 ± 14	29 ± 16.6	-36 ± 6.609
Meisel et al, 2006 (62)	12	59.45 ± 22.76	12.82 ± 19.37	21.0 22.85	18.0 ± 18.73	-41.45 ± 8.509
Noriega et al, 2017 (85)	13	67 ± 24.25	43 ± 31.17	40 ± 27.71	47 ± 34.64	-20.0 ± 11.768
Orozco et al, 2011 (84)	10	68.9 ± 10.43	26.5 ± 17.7	21.6 ± 18.97	20.0 ± 20.55	-48.9 ± 7.288
Pettine et al, 2017 (77)	21	81.5 ± 13.25	27.0	18.7	28.1 ± 33.80	-53.4 ± 7.92#

- Standard deviation estimated from graph - $ - utilized from Wu et al (61)

Appendix Table 9. Studies of cell therapy in lumbar discogenic pain with average Oswestry Disability Index (0-100) (mean ± SD) at different points.

Study Name	N	Base	3 months	6 months	12 months	Difference in means from 12 months to Baseline (mean ± SE)
Coric et al, 2013 (83)	15	53.3	27.6	26.9	20.3	-27.649 ± 0.555$
Kumar et al, 2017 (86)	10	42.8 ± 15.03	31.7 ± 14.22	21.3 ± 7.42	16.8 ±9.77	-26.0 ± 5.672
Meisel et al, 2006 (62)	12	56.83±18.6	13.45 ± 17.11	18.64 ± 21.53	15.64 ± 16.92 (11)	-41.19 ± 7.438
Noriega et al, 2017 (85)	13	34 ± 24.28	16 ± 17.32	20 ± 24.28	22 ± 24.28	-12.0 ± 9.523
Orozco et al, 2011 (84)	10	25.0 ± 12.96	13.0 ± 10.12	9.4 ± 8.54	7.4 ± 7.27	-17.6 ± 4.699#
Pettine et al, 2017 (77)	21	56.2 ±18.35	22.8 (26)	24.4 (26)	22.3 ± 33.80	-33.9 ± 8.393

- Standard deviation estimated from graph - $ - utilized from Wu et al (61)

Appendix Table 10. Studies of epidural injections of PRP in lumbar disc herniation with average pain scores.

	n	Baseline	3 months	6 months	12 months	24 months
Kumar et al, 2015 (100)	20	6.95 ± 1.13*	2.55	2.0 ± 1.3*	--	--
Becker et al, 2007 (101)	32	77.8 ± 16.4		23.3 ± 24.8	--	--
Kirchner and Anitua, 2016 (92)	86	8.4 1.1	1.7 ± 2.3	0.8 ± 1.7	--	--
Centeno et al, 2017 (99)	470	5.1 ± 2.4 (n=303)	3.4 (n=192)	3.2 (n=181)	3.0 (n=174)	2.5 (n=126)
Bhatia & Chopra, 2016 (98)	10	6.1 ± 1.197	3.79 ± 1.197	--	--	--

HS Kumar 1976 –– SD estimated graph - Centeno 2017 SD are not available

Appendix Table 11. Studies of epidural injections of PRP in lumbar disc herniation with Oswestry Disability Index.

	N	Baseline	3 months	6 months
Kumar et al, 2015 (100)	20	27.9 ± 8.5	10.5	8.5 ± 8.81
Becker et al, 2007 (101)	32	22.0 ± 8.3	11.2 ± 10.2	11.7 ± 9.2
Bhatia & Chopra, 2016 (98)	10	49.2 ± 9.624	29.5 ± 11.65	
Centeno et al, 2017 (99)	470	NA – FRI?		

Only 2 studies provided ODI for 6 months follow-up